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CMV is the leading cause of both non-hereditary mental retardation and 
hearing loss and CMV infection following transplantation carries a serious risk for 
complications. The development of a CMV vaccine or better therapeutic 
treatment is desired but to develop these a more complete understanding of 
CMV pathogenesis is necessary. Sequence comparisons between attenuated 
and virulent strains of HCMV map major differences to a 15kb region (ULb’) 
containing the chemokine homolog, vCXCL-1. The vCXCL-1 protein of the 
Toledo (Tol) strain was previously shown to function in vitro as a CXC 
chemokine. Murine CMV (MCMV) also encodes a viral chemokine, MCK2. Prior 
research has shown that infection of mice with a recombinant MCMV, RM4511, 
which lacks a functional MCK2, resulted in decreased inflammation at the site of 
infection and decreased dissemination to the salivary gland. Analysis of the role 
of vCXCL-1 in the context of HCMV infection is limited by the species specificity 
of the CMVs. One possible model system for analyzing the function of this 
chemokine is the chimpanzee model of CMV infection. Chimpanzee CMV 
(CCMV) has at least one gene with similarity to the vCXCL-1 gene of the Toledo 
strain of HCMV. The hypothesis of this study was that vCXCL-1CCMV is a 
functional CXC chemokine that contributes to viral dissemination. To address this 
we initially compared the functional and biochemical characteristics in vitro of 
vCXCL-1 from Toledo HCMV (vCXCL-1Tol) and CCMV (vCXCL-1CCMV) by 
analyzing receptor binding, activation, chemotaxis, signaling, and anti apoptotic 
suppression in neutrophils. The CCMV chemokine had a ~70-fold lower affinity 
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for human CXCR2 compared to vCXCL-1Tol. Nevertheless, the homologs 
functioned very similarly and we only observed differences in integrin induction 
and the ability of the two chemokines to reduce neutrophil apoptosis. We 
evaluated the in vivo function of vCXCL-1CCMV using MCMV infection in mice. 
Due to the strict species specificity of CMV we used MCMV RM4511 to produce 
recombinant MCMVs expressing vCXCL-1CCMV or a control host chemokine, 
mCXCL1, under the control of the HCMV IE promoter. RMvCXCL1CCMV and 
RMmCXCL1 grew with similar kinetics to RM4511 in cell culture and expressed 
vCXCL-1CCMV and mCXCL1, respectively. Primary dissemination of 
RMvCXCL1CCMV and RMmCXCL1 was similar to RM4511 but neither 
recombinant was recovered from the salivary gland at any time point. 
Maintenance of this phenotype in SCID mice showed the recombinant viruses 
were not cleared from the salivary gland by the adaptive immune response. 
RMvCXCL1CCMV and RMmCXCL1 were also not recovered in neutrophil-depleted 
mice, although RM4511 titers were reduced in these mice indicating neutrophils 
may play a role in dissemination of MCMV to the salivary gland. This study is the 
first to characterize the CCMV viral chemokine, vCXCL-1, and show it is 
functionally similar to vCXCL-1Tol. This provides evidence that the study of 
vCXCL-1CCMV may contribute to a better understanding of its HCMV homolog. 
Furthermore, this research is the first to evaluate the role of a CMV CXC 
chemokine in vivo. Future work aimed at evaluating the role of other viral and 
host chemokines in vivo using the mouse model will likely advance our 
understanding of viral chemokines and their role in virus-host interactions. 
 vi
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In the early 20th century researchers noted features characteristic of 
cytomegalovirus (CMV) cytopathology in infants with what was later referred to 
as cytomegalic inclusion disease (CID). However, CMV wasn’t determined to be 
the etiologic agent of CID until three groups independently isolated the virus in 
tissue culture in 1956 (Craig et al., 1957; Rowe et al., 1956; Smith, 1956). At 
present, CMV is the most common congenitally acquired infection in the United 
States and many other developed countries. Although the majority of these 
infections are inapparent, symptomatic infections carry a high risk of central 
nervous system  (CNS) damage that can lead to long-term sequelae including 
hearing loss and mental retardation. As a result, CMV is the leading cause of 
both non-hereditary mental retardation and hearing loss. It is estimated as many 
as 8000 children are born each year in the U.S. alone with CNS damage due to 
congenital CMV infection (Arvin et al., 2004). Furthermore, up to 5% of 
symptomatic infants die (Ross and Boppana, 2005). 
Besides congenital infections, CMV is also considered one of the most 
significant infectious diseases of immunocompromised individuals particularly 
among transplant patients. Up to 50% of kidney recipients acquire a primary 
CMV infection following transplantation and this carries a serious risk for 
complications (Ho, 1991). However, perhaps the most severe outcomes occur in 
bone marrow recipients who develop pneumonia that has a mortality rate 
exceeding 80% (Ho, 2008).  
Treatment of CMV related illness consists of a few antiviral agents such as 
ganciclovir that inhibit the viral DNA polymerase. Although prophylactic use of 
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these drugs has contributed to a decline of CMV disease in immunocompromised 
individuals, delayed onset of disease occurs in some patients following 
completion of prophylactic treatment (Limaye et al., 2004). Administration of 
these therapeutics can also result in organ toxicity and their long-term use is 
associated with drug resistance (Coen, 2007). Furthermore, no treatment 
regimen has to date been approved for cases of congenital infection (Edward S. 
Mocarski, 2007).  
A primary goal in the management of CMV is the implementation of a 
vaccination program (Arvin et al., 2004). An example of vaccination for the 
prevention of congenital infection is the rubella vaccine. This is routinely given as 
part of the MMR vaccination regime.  Rubella, a member of the paramyoxvirus 
family, causes many of the same detrimental outcomes as CMV congenital 
infection. Rubella was once the most common congenitally acquired viral 
infection but the development of a rubella vaccine has led to the elimination of 
this virus in the U.S (Plotkin, 2006). However, unlike rubella, for which a vaccine 
was available just a few years following isolation of the virus, no vaccine against 
CMV is currently available despite over three decades of effort. 
A major obstacle in the design of a vaccine against CMV is the 
complicated relationship between the virus and its host. CMV remains latent in 
the host and although acute infection may be controlled, the virus is not 
eliminated and can reactivate when the host’s immune system becomes 
compromised. Additionally, the genome of CMV is large and contains numerous 
genes involved in altering the host immune response during viral infection 
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(Banatvala and Brown, 2004). These include homologs of host proteins, such as 
cytokine and chemokine receptors, and the focus of this thesis, chemokine 
homologs (Alcami and Koszinowski, 2000). Evaluating the function of these viral 
proteins will contribute to our understanding of CMV pathogenesis and provide 
insight into the host immune response to viral infection that may ultimately 
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Genome and Structure 
Cytomegaloviruses are classified within the -herpesvirus subfamily of 
herpesviruses along with human herpesviruses 6 and 7. Characteristic features 
of this virus subfamily include a narrow host range as well as slow growth in cell 
culture (Edward S. Mocarski, 2001). Cytomegaloviruses infect a wide range of 
hosts. These include the cytomegaloviruses of various primates such as human 
(HCMV or human herpesvirus 5) and chimpanzee cytomegalovirus (CCMV) and 
the muromegaloviruses that infect rodents such as murine cytomegalovirus 
(MCMV) (Edward S. Mocarski, 2007).  
As with all herpesviruses, the CMV genome is a linear, dsDNA molecule 
that varies in size depending on the species. The genome of HCMV is 
approximately 240 kilobase pairs (kbp) and is unusual among most CMVs in its 
genome organization. The genome occurs as two main segments, the unique 
long (UL) and unique short (US) regions that are flanked on both sides by inverted 
repeats. Four different isomers of the genome can occur due to inversion of the 
UL and US segments at the repeat junctions (Landolfo et al., 2003). Clinical 
strains and the low passage lab strain, HCMVToledo, are missing a portion of the 
internal repeat and instead contain an additional 15 kbp of DNA. CCMV is the 
nearest relative to HCMV and has a similar genome size and configuration (Cha 
et al., 1996). In contrast, the genome of MCMV occurs as a single unique 
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sequence without internal repeats and only short direct repeats at the genome 
termini (Ebeling et al., 1983). 
The CMV genome is encapsidated within an icosahedral nucleocapsid. 
The nucleocapsid is comprised of seven proteins, including the herpesvirus-
conserved major and minor capsid proteins (Edward S. Mocarski, 2001). The 
capsid is surrounded by a protein-rich tegument layer that is enclosed within an 
envelope membrane. Infectious virions contain at least thirty proteins, the 
majority of which form the tegument layer. Tegument proteins serve various roles 
and function in viral entry as well as modifying the host cell response upon virus 
entry (Edward S. Mocarski, 2007). The surrounding envelope contains proteins of 
both viral and cellular origin, the most abundant of which is the viral glycoprotein 
B (gB), which is used for viral attachment and entry (Gibson, 1983). 
DNA replication proceeds from the origin of replication, oriLyt (Hamzeh et 
al., 1990). Expression of viral gene products is temporally regulated in a similar 
manner to other herpesviruses and the genes are classified as immediate early, 
early, and late genes. The major immediate early genes, IE1 and IE2 in HCMV, 
are important transactivators of other viral gene products and transactivate early 
and late genes. The early genes encode nonstructural proteins that contribute to 
genome replication. Expression of late genes is dependent on viral replication 
and encode the structural proteins and other proteins involved in virion assembly 
(Edward S. Mocarski, 2001). 
Human fibroblasts are permissive for HCMV and are commonly used in 
cell culture, although a number of different cell types are permissive in vivo 
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including endothelial cells, epithelial cells, smooth muscle cells, and 
macrophages (Pass, 2001; Sinzger et al., 1995). Entry into the host cell is 
initiated by the association of gB with the proteoglycan, heparan sulfate, on the 
cell surface (Compton, Nowlin, and Cooper, 1993). However, this interaction is 
not sufficient for infection and interactions with additional host receptors are 
needed for virus fusion and entry into the cell. Recently, epidermal growth factor 
receptor  (EGFR) and members of the  integrin family have been found to 
mediate virus entry although both receptors are not expressed on all permissive 
cell types (Bentz and Yurochko, 2008; Feire, Koss, and Compton, 2004; Wang et 
al., 2005; Wang et al., 2003). The tegument and nucleocapsid are released into 
the cytoplasm and the nucleocapsid is transported to the nucleus where viral 
replication occurs. Following replication of the genome and production of the 
virion proteins, virion assembly occurs in the nucleus. Genome-length DNA 
molecules are packaged from genome concatemers into preformed 
nucleocapsids. Virions acquire a primary envelope as they bud from the nuclear 
membrane, which is subsequently shed, and the final envelope is obtained in the 
golgi network (AuCoin et al., 2006). Nuclear and perinuclear inclusions, 
characteristics of cytomegalovirus cytopathic effect (CPE), result from the 
accumulation of nucleocapsids in the nucleus or golgi prior to release from the 
cell. Mature virions are carried to the plasma membrane in endocytic vesicles 
and released from the cell by exocytosis (Edward S. Mocarski, 2007). 
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Epidemiology and Disease 
The presence of HCMV in human populations is ubiquitous and rates of 
infection can approach 100% particularly in developing countries or populations 
of low socioeconomic status within developed countries (Pass, 1985; Staras et 
al., 2006). Despite this frequency, CMV is not highly contagious and transmission 
occurs following close contact with an infected individual shedding virus in bodily 
fluids such as saliva or urine (Pass, 2001). A particularly important means of 
transmission occurs among children and their caregivers, for instance in day care 
centers, and is likely due to the prolonged shedding of virus in children as well as 
the frequent contact with bodily fluids that occurs in this setting (Pass et al., 
1984). Day care workers show higher rates of infection compared to the 
expected transmission rate in adults (Adler, 1989). CMV transmission is also 
associated with sexual activity and is more prevalent among individuals with 
multiple partners or those with sexually transmitted diseases (Chandler et al., 
1985; Pereira et al., 1990). 
HCMV can also be transmitted vertically from mother to child via 
postpartum, intrapartum, or transplacental transmission, the latter transmission 
route being uncommon with other herpesviruses. Postpartum transmission of 
CMV during breastfeeding is the most common route of transfer from mother to 
child (Pass, 2001). Transmission is related in part to the duration of 
breastfeeding with rates of infection increasing from 0% to 39% after just one 
month of nursing. Additionally, more infants become infected when virus is 
detectable in the breast milk (Dworsky et al., 1983). Intrapartum transmission 
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occurs in up to 50% of cases when virus is present in the genital tract during 
delivery although shedding from this site occurs infrequently in women over the 
age of 30 (Reynolds et al., 1973). Finally, CMV is also transferred by 
transplacental infection of the fetus. From 20 to 40% of women who acquire a 
primary CMV infection during pregnancy will transmit virus to their fetus. 
Congenital infections also occur from viral reactivation during pregnancy but at a 
considerably lower rate than primary infection (Pereira et al., 2005). 
CMV is also a frequently encountered opportunistic pathogen in 
immunocompromised individuals. All patients undergoing solid organ or 
hematopoietic stem cell transplantation are at risk of complications from CMV 
infection. Infection can be due to reactivation of latent CMV of the recipient or 
transmission of CMV present in the transplanted organ (Landolfo et al., 2003). 
Primary infection of a seronegative recipient typically carries the greatest risk for 
severe disease. Importantly, the incidence of CMV disease in transplant patients 
has declined due to improved screening of donor organs and blood products as 
well as the effective use of antiviral drugs (Pereyra and Rubin, 2004). CMV has 
also been a common problem in individuals with HIV or AIDS. As many as 20 – 
40% of adults with AIDS developed CMV disease prior to the use of highly active 
antiretroviral therapy (HAART) (Edward S. Mocarski, 2007). HAART treatment 
preserves the immune function of those with HIV and has greatly reduced the 
incidence of CMV disease in this group (Gerna et al., 1998). Nevertheless, 
individuals with severe immune dysfunction due to AIDS are still at considerable 
risk for complications from CMV infection. 
 11
Disease due to CMV varies in severity and primarily depends on the 
immune status of the individual. CMV infection in the immunocompetent host is 
largely asymptomatic (Stagno et al., 1986). However, mononucleosis develops in 
some individuals and is the most common clinical outcome. Life-threatening 
systemic infections rarely occur (Edward S. Mocarski, 2007). CMV disease in the 
newborn depends largely on the route of transmission. While peri- or postpartum 
transmission is generally inapparent, congenital infection can result in serious 
outcomes. Primary infection during pregnancy carries the greatest risk for 
symptomatic disease in the newborn and can result in permanent defects such 
as mental retardation, and hearing or vision loss (Revello and Gerna, 2002). 
Likewise, CMV infection in the immunocompromised host can have severe 
consequences. CMV in solid organ transplant recipients can result in systemic 
disease and increases the likelihood of organ rejection.  CMV infection has also 
been associated with an increased risk of coronary artery disease in heart 
transplant patients (Grattan et al., 1989). Hematopoietic stem cell recipients 
infected with CMV frequently present with pneumonitis or gastritis (Ljungman, 
1996). CMV is also associated with an increased risk for opportunistic infections 
in both transplant groups (Ljungman, Griffiths, and Paya, 2002). CMV disease in 
individuals with HIV manifests most often as retinitis (Cheung and Teich, 1999). 
Furthermore, an association between CMV and the progression of HIV infection 
has been suggested although definitive evidence identifying HCMV as a risk 
factor is still lacking (Pass, 2001). 
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Dissemination 
HCMV is acquired naturally through infection of the genitourinary and 
respiratory tracts where it replicates efficiently within epithelial cells at these 
sites. The process whereby HCMV disseminates to other organs from the initial 
site of infection is incompletely understood but is thought to occur following a 
viremic stage (i.e. virus present in the blood).  The current model of HCMV 
dissemination is based in part on studies of MCMV. Dissemination of MCMV 
occurs by a biphasic viremia, initially seeding organs such as the liver and spleen 
followed by a secondary viremia seeding the salivary glands (Collins, Quirk, and 
Jordan, 1994). This dissemination is exclusively cell associated. Whether HCMV 
viremia is temporally regulated in this manner is unknown.  
Evidence of the mechanism of HCMV dissemination is implied from 
clinical data. Clinical observations provided early evidence for the transmission of 
CMV via the bloodstream. It is well established that seronegative individuals can 
acquire CMV following blood transfusions from seropositive donors (Meyers, 
Flournoy, and Thomas, 1986). Depletion of leukocytes from seropositive blood 
markedly decreases the incidence of such infections (Bowden et al., 1995; 
Gilbert et al., 1989). These findings and the inability to detect free virus within the 
blood even during acute infection indicate the virus is cell-associated (Howell, 
Miller, and Martin, 1979; Rinaldo, Black, and Hirsch, 1977). In individuals with 
detectable viremia, HCMV is most often isolated from neutrophils and monocytes 
(Gerna, Baldanti, and Revello, 2004). Viral DNA can be detected in both cell 
populations although DNA levels are often higher in neutrophils than monocytes. 
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Likewise, infectious virus is isolated more often from neutrophils (Dankner et al., 
1990; Saltzman, Quirk, and Jordan, 1988). Rat cytomegalovirus (RCMV) and 
MCMV have been detected in these cell types as well, although recovery of 
MCMV is highest in monocytes rather than neutrophils (Bale and O'Neil, 1989; 
Collins, Quirk, and Jordan, 1994; Stoddart et al., 1994; van der Strate et al., 
2003). The detection of HCMV DNA (DNAemia) or the viral structural protein, 
pp65, (antigenemia) in neutrophils is considered diagnostic of viremia (Boivin et 
al., 1998; Gerna et al., 1990; Grazia Revello et al., 1989). Despite a clear 
association of CMV with neutrophils during acute infection, an inability to detect 
viral DNA in neutrophils of healthy, seropositive individuals suggests CMV does 
not persist in these cells (Taylor-Wiedeman et al., 1993). In contrast, the 
presence of viral DNA in monocytes and myelomonocytic progenitor cells of 
healthy subjects has been demonstrated (Kondo, Xu, and Mocarski, 1996; 
Taylor-Wiedeman et al., 1991; von Laer et al., 1995a). Additionally, virus can be 
recovered from these cell types following prolonged cocultivation in vitro with 
permissive cell monolayers. These assays have led to the conclusion that 
monocytes and their progenitors are the likely reservoirs for latent CMV (Kondo, 
Kaneshima, and Mocarski, 1994). Again demonstrating the similarities between 
MCMV and HCMV, MCMV has been identified in macrophages and bone marrow 
progenitor cells of latently infected mice (Koffron et al., 1998; Mitchell, Leung, 
and Stevens, 1996; Pollock et al., 1997). 
Viral replication in neutrophils is generally considered abortive with 
transcription confined to immediate early genes (Grefte et al., 1994; Sinzger et 
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al., 1995). However, results have been inconsistent with some groups also 
reporting the detection of early and late viral transcripts (Dankner et al., 1990; 
von Laer et al., 1995b). A decrease in IE transcripts was found when HCMV-
infected neutrophils were treated with transcriptional and translational inhibitors, 
while no change was noted in late gene products consistent with active 
transcription of only the IE genes. It was suggested neutrophils acquire early and 
late transcripts by direct transmission from infected cells permissive for 
replication or from phagocytosis of such cells (Gerna et al., 2000). In spite of its 
inability to replicate HCMV, neutrophils isolated from viremic individuals are able 
to transmit infectious virus. Thus neutrophils may have a role in disseminating 
HCMV (Gerna et al., 1990; Saltzman, Quirk, and Jordan, 1988).  
Like neutrophils, infection of monocytes leads to abortive replication, but 
upon their differentiation into macrophages these cells become permissive 
(Gerna et al., 1992; Grefte et al., 1994; Ibanez et al., 1991; Taylor-Wiedeman, 
Sissons, and Sinclair, 1994; Zhuravskaya et al., 1997). One group found that 
HCMV infection of monocytes induced their differentiation into macrophages 
(Smith et al., 2004). Therefore, migration of infected monocytes into tissues and 
their subsequent differentiation into macrophages could support viral replication 
at these sites and CMV may promote this process.  
How neutrophils and monocytes acquire HCMV is controversial. An early 
report of a patient with fatal CMV disease identified CMV virions in the 
phagosomes of neutrophils (Martin et al., 1984). However, no other group has 
reported similar findings. In vitro studies have shown uptake of free virus by 
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neutrophils is minimal suggesting phagocytosis is not likely the main source of 
CMV present in neutrophils (Grundy et al., 1998). Rather, transmission of CMV to 
neutrophils as well as monocytes is thought to primarily occur following direct 
contact with infected cells (Digel et al., 2006). Endothelial cells are a natural site 
of CMV infection in vivo and may facilitate dissemination of CMV via neutrophils 
or monocytes (Fish et al., 1995; Jarvis and Nelson, 2002; Sinzger et al., 1995). In 
vitro, CMV-infected endothelial cell monolayers were found to transmit virus to 
neutrophils following co-culture or transmigration assays. Subsequent transfer of 
CMV from the infected neutrophils to fibroblast monolayers indicated the 
presence of infectious virions (Gerna et al., 2000; Grundy et al., 1998). Similar 
findings have been reported following co-culture of monocytes with infected 
endothelial cells (Bentz et al., 2006; Waldman et al., 1995). Furthermore, both 
neutrophils and monocytes exhibit enhanced migration across endothelial cells 
infected with CMV (Bentz et al., 2006; Craigen et al., 1997). Expression of the 
chemokine, CXCL8, is upregulated in CMV-infected endothelial cells and could 
recruit neutrophils to the site of infection (Grundy et al., 1998). Additionally, 
HCMV encodes a chemokine homolog, vCXCL-1, able to induce migration of 
neutrophils in vitro (Penfold et al., 1999). Similarly, the MCMV chemokine 
homolog, MCK2, was found to augment viremia and the recruitment of monocytic 
progenitor cells to the site of infection (Fleming et al., 1999; Saederup et al., 
2001).  
Collectively these data have led to a proposed model of CMV 
dissemination from the infected mucosa. CMV at the epithelial surface initially 
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spreads to the endothelium. Infected endothelial cells recruit leukocytes, 
particularly neutrophils and monocytes, and this may be facilitated or enhanced 
by virally encoded chemokines. Neutrophils and monocytes acquire infectious 
CMV upon contact with infected endothelial cells. These cells then disseminate 
the virus through the bloodstream and can migrate across the endothelium 
seeding various tissues (Figure 1). During transmigration, the differentiation of 
monocytes into the permissive macrophage could further enhance the replication 
of CMV within the tissues. In addition to being a model for viral dissemination 
during acute infection, this model offers an explanation for dissemination of 
reactivated CMV present in monocytes or monocyte progenitor cells (Grundy et 
al., 1998; Pass, 2001; Smith et al., 2004). 
 
Chemokines and Chemokine Receptors 
Chemokines 
Chemokines are small chemotactic cytokines produced by leukocytes and 
other cells that typically range in size from 9-130 amino acids. The first 
chemokine to be identified was CXCL4 (previously platelet factor 4) an 
angiostatic chemokine stored in the  granules of platelets (Walz et al., 1977). 
However, it wasn’t until the discovery of CXCL8 (IL-8) in 1987 that this class of 
proteins was found to have chemotactic properties (Schroder et al., 1987). To 


















Figure 1. Proposed model of CMV dissemination. The infected epithelium 
transmits CMV (·) to endothelial cells (EC). Leukocytes, including neutrophils (N) 
and monocytes, are recruited by host (such as CXCL8) or viral chemokines 
secreted by ECs. Infected ECs (black cells) transmit CMV via direct contact with 
these cells. Infected leukocytes then disseminate CMV via the bloodstream (A) or 












Table 1. The known human chemokine receptors and some of their ligands 
(adapted from Rossi and Zlotnik, 2000). 
Chemokine Receptors Human Chemokine Ligands 
CXCR1 CXCL8, CXCL6 
CXCR2 CXCL8, CXCL6, CXCL1, CXCL2, CXCL3, CXCL5




CCR1 CCL3, CCL4, CCL5, CCL14, CCL15, CCL16 
CCR2 CCL2, CCL8, CCL7, CCL13 
CCR3 CCL11, CCL24, CCL7 
CCR4 CCL17, CCL22, CCL3, CCL5 
CCR5 CCL3, CCL4, CCL5 
CCR6 CCL20 
CCR7 CCL19, CCL21 
CCR8 CCL1 
CCR9 CCL25 
CCR10 CCL27, CCL28 
  
XCR1 XCL1, XCL2 
CX3CR1 CX3CL1 
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Chemokines are divided into four main groups based on the spacing of 
their conserved cysteine residues. The two largest groups, the CC and CXC 
chemokines, are so named because the two conserved amino terminal cysteines 
are either adjacent (CC) or separated by an intervening amino acid (CXC) 
(Baggiolini, 1998). CXC chemokines can be further subdivided into ELR (+) or (-) 
dependent upon the presence of a glutamate-leucine-arginine motif directly 
preceding the CXC motif. ELR CXC chemokines, such as CXCL8 and CXCL1 
(Gro), primarily attract neutrophils, although some members of this group also 
have angiogenic properties through their recruitment of endothelial cells (Strieter 
et al., 1995a). In contrast, many non ELR CXC chemokines are angiostatic and 
almost exclusively attract cells other than neutrophils. The CC chemokines are 
the largest group and attract a variety of cell types including monocytes, 
basophils, eosinophils, and dendritic cells (Murphy, 2003). The third chemokine 
class, CX3C, has three amino acids separating the first two cysteines and has 
only one member, CX3CL1 or fractalkine (Bazan et al., 1997). Fractalkine, as well 
as CXCL16, are unique in that the chemokine domain of these proteins is linked 
to a mucin-like stalk that anchors the chemokine to the cell membrane through its 
transmembrane region. CX3CL1 can also be enzymatically cleaved from the 
membrane and function as a soluble factor (Charo and Ransohoff, 2006). Lastly, 
XCL1 and 2 (lymphotactin  and ) are the sole members of the C chemokine 
group and contain only two cysteines (Kelner et al., 1994). 
Chemokines are important in the regulation of a number of biological 
processes, the most well known being chemotaxis. Chemokine gradients provide 
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for the directed movement of cells through the blood or tissues. Although 
chemokines are secreted, they can bind glycosaminoglycans (GAGs) such as 
heparan sulfate present on the cell surface or within the extracellular matrix 
creating a solid support for gradient formation as well as receptor interactions 
(Huber et al., 1991; Webb, Clark-Lewis, and Alcami, 2003). In one experiment, 
mutants of CCL2, CCL4, and CCL5 that inefficiently bind GAGs induced 
chemotaxis in vitro but recruited far fewer cells compared to wild type 
chemokines when injected into the peritoneum of mice, highlighting the 
importance of the chemokine-GAG interaction in vivo (Proudfoot et al., 2003).  
Chemokines also promote cell migration through their effect on leukocyte 
adhesion molecules, such as the 2-integrins, CD11a, b, and c. Activated 2-
integrins bind their ligands on endothelial cells resulting in “tight binding” of the 
two cells, a crucial step in the transmigration of leukocytes into tissues (Ley et al., 
2007). Chemokine-mediated “inside-out” signaling induces conformation changes 
in the 2-integrins allowing the high affinity ligand binding needed for cell arrest 
(Laudanna et al., 2002). Additionally, chemokines such as CXCL8 have been 
found to upregulate the expression of 2-integrins on cells such as neutrophils 
(Springer, 1994). The importance of chemokines in orchestrating cell trafficking 
during inflammation is well established. Microbial products and inflammatory 
cytokines like TNF induce the expression of chemokines and their receptors to 
initiate the inflammatory response (Baggiolini, 2001). However, it has become 
increasingly clear chemokines are necessary for efficient homing of leukocytes 
during homeostasis. For instance, the migration of T cells to secondary lymphoid 
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tissues depends on CCL19 and CCL21 and B cell migration is regulated by 
CXCL12 (von Andrian and Mempel, 2003). 
In addition to cellular trafficking, chemokines promote the effector 
functions of cells. Cellular activation in response to chemokines can cause the 
exocytosis of granules containing a host of preformed mediators, which may 
amplify the inflammatory response (Bokoch, 1995). In neutrophils, these 
mediators include antimicrobial proteins such as defensins and lysozyme as well 
as proteases capable of degrading proteins of the extracellular matrix and 
basement membrane (Witko-Sarsat et al., 2000). Chemokines may also trigger 
the formation of reactive oxygen species, oxygen metabolites with potent 
antimicrobial activities. Initiation of this “respiratory burst” occurs upon assembly 
of the enzyme NADPH oxidase. NADPH oxidase catalyzes the formation of the 
unstable superoxide anion, which reacts to produce additional microbicidal 
molecules (Baggiolini et al., 1993). 
Chemokine Receptors 
Chemokines bind and signal via receptors of the seven transmembrane G 
protein coupled receptor (GPCR) family. Chemokine receptors are classified 
according to the chemokine class with which they interact. Therefore, CXC 
chemokines bind CXC receptors and so forth. Chemokine receptors typically bind 
multiple ligands and thus there are far fewer receptors than chemokines (Murphy, 
2002). These receptors have cytoplasmic domains that interact with 
heterotrimeric G proteins consisting of , , and  subunits. Conformational 
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changes in the receptor upon chemokine binding result in its interaction with a 
GDP bound G protein. The receptor functions as a guanine nucleotide exchange 
factor (GEF), facilitating the exchange of GDP for GTP. This results in the 
dissociation of the G and G subunits. Both subunits can mediate downstream 
signaling events (Ben-Baruch, Michiel, and Oppenheim, 1995; Gether, 2000). 
Following chemokine receptor activation, the G subunit regulates a 
number of signaling pathways. G mediates the phosphorylation of 
phospholipase C (PLC). Activated PLC hydrolyzes phosphotidylinositol 4,5-
bisphosphate (PIP2) to produce inositol triphosphate (IP3) and diacylglycerol 
(DAG). IP3 triggers the transient release of Ca
2+ from the endoplasmic reticulum 
into the cytoplasm, which is frequently used as a marker of cellular activation. 
DAG activates members of the protein kinase C (PKC) family (Murdoch and Finn, 
2000). PKC activation enhances ROS production and has been shown to 
upregulate CD11b/CD18 in neutrophils (Takami, Terry, and Petruzzelli, 2002). 
The G subunit also initiates phosphotidylinositol 3-kinase (PI3K) activity. PI3K 
phosphorylates PIP2 generating phosphotidylinositol 3,4,5-triphosphate (PIP3). 
PIP3 accumulation at the leading edge of neutrophils confers polarity and is 
important for chemotaxis (Weiner et al., 2002). Nevertheless, other pathways are 
likely important for chemotaxis as the migration of cells isolated from PI3K knock-
out mice is impaired although not completely eliminated. PIP3 also recruits 
additional effectors to the plasma membrane such as protein kinase B (PKB or 
Akt) (Mellado et al., 2001). Akt induces anti-apoptotic mechanisms that promote 
cell survival, although the ultimate fate of the cell is determined by input from 
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multiple pathways (Mayadas and Cullere, 2005; Vlahakis et al., 2002). MAP 
kinase (MAPK) activity is also stimulated upon receptor signaling. In transfected 
Cos-7 cells, Gi subunits were unable to stimulate MAPK consistent with a role 
for G in activating this pathway (Koch et al., 1994). In particular, PI3K can 
phosphorylate the small G protein, Ras, which subsequently initiates the MAPK 
pathway by binding to the MAPKKK, Raf. Like Akt, activation of the MAPKs, ERK 
1 and 2, generates signals that protect the cell from apoptosis (Bokoch, 1995; 
Vlahakis et al., 2002). Additionally, ERK1/2 stimulate integrin-dependent 
adhesion of cells following chemokine activation (Takami, Terry, and Petruzzelli, 
2002). 
The G subunit has GTPase activity and can hydrolyze GTP to GDP 
resulting in the reassociation of the G and G subunits and termination of the 
signal. Additionally, G protein receptor kinases (GRKs) may phosphorylate serine 
and threonine residues in the c-terminus of the receptor to which  arrestins may 
bind.  arrestins prevent association of the G protein with the receptor leaving the 
receptor refractory to subsequent stimulation. Additionally,  arrestins can 
coordinate receptor internalization. This results in the degradation of the receptor 
or dephosphorylation and recycling of the receptor to the cell surface (Neel et al., 
2005). Recently,  arrestins have also been shown to act as adaptor proteins 
capable of mediating signaling events downstream of the chemokine receptor 
(Lefkowitz and Shenoy, 2005). 
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Receptor signaling requires the interaction of the receptor with multiple 
motifs present on the chemokine. Residues in the N-loop, a region that follows 
the first two cysteines, mediate chemokine binding and can determine receptor 
specificity (Fernandez and Lolis, 2002). For instance, when portions of the N-
loops of CXCL8 or CXCL1 were interchanged these chemokines showed a 
reverse in their patterns of receptor binding and specificity (Lowman et al., 1996). 
In addition, activation of the receptor requires residues in the N-terminus of the 
chemokine. In the case of CXCL12, truncation of the first amino-terminal residue 
is sufficient to produce a receptor antagonist (Crump et al., 1997). Alternatively, a 
CCL5 antagonist was generated by the extension of the N-terminus by a single 
amino acid (Proudfoot et al., 1996). The ELR motif preceding the first cysteine in 
certain CXC chemokines is another important determinant of receptor activation 
and mutation of these residues impairs the ability of these chemokines to bind 
and stimulate their receptors (Clark-Lewis et al., 1991; Hebert, Vitangcol, and 
Baker, 1991; Schraufstatter et al., 1993). Nevertheless, other regions within the 
chemokine also contribute to receptor interactions as synthetic peptides 
comprising the N-terminus and the N-loop have reduced activities compared to 
their full-length counterparts (Baggiolini, Dewald, and Moser, 1997). 
 
Viral Chemokine Homologs 
HCMV encodes two ORFS with homology to CXC chemokines, UL146 
and UL147 (Cha et al., 1996).  Chimpanzee CMV encodes homologs of UL146 
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and UL147 as well as the related gene UL146a. While no functional data is 
available for UL147, analysis of the protein product of HCMV UL146, vCXCL-1, 
demonstrated its capacity as a functional chemokine. vCXCL-1 was shown to 
bind exclusively to hCXCR2 with an affinity similar to that of the host chemokine, 
CXCL8. Additionally, vCXCL-1 was able to induce chemotaxis and intracellular 
calcium release in human neutrophils, again to levels comparable to host 
chemokines (Penfold et al., 1999). The function of the HCMV vCXCL-1 in vitro 
suggests the potential for this viral chemokine to alter the response of neutrophils 
in the course of CMV infection. A mutant HCMV virus with a deletion of UL146-
UL147 was not transmitted to neutrophils but retained its tropism for other cell 
types providing additional evidence these proteins facilitate an interaction of CMV 
with neutrophils (Hahn et al., 2004). 
Due to the strict species specificity of CMV, in vivo characterization of 
UL146 and UL147 has been limited to sequence analysis of clinical HCMV 
isolates. UL146 is highly variable, differing as much as 60% among isolates (Heo 
et al., 2008). It was postulated that this variability might correlate with the severity 
of CMV disease however no clear relationship in this regard has been identified 
(Arav-Boger, Zong, and Foster, 2005; Bale et al., 2001; Hassan-Walker et al., 
2004). 
HCMV also encodes genes with limited homology to CC chemokines. 
UL128 and UL130 both have signal sequences and conserved cysteine motifs 
similar to CC chemokines (Akter et al., 2003). It has yet to be determined 
whether these proteins function as chemokines. Interestingly, the UL128-131 
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locus was found to be necessary for endothelial cell and leukocyte tropism based 
on the inability of HCMV UL128-131 deletion mutants to infect these cell types 
(Hahn et al., 2004). This likely explains the loss of endothelial cell tropism in lab-
adapted strains of HCMV, a number of which were shown to have deletions or 
mutations in at least one gene from this region (Akter et al., 2003). The UL128-
131 proteins have recently been shown to interact with gH/gL complexes that 
mediate entry of CMV into endothelial and epithelial cells, in contrast to the 
gH/gL/gO complexes that mediate virus entry into fibroblasts (Wang and Shenk, 
2005a; Wang and Shenk, 2005b).  
The best characterized of the CMV chemokines is the CC chemokine 
homolog of MCMV. Originally identified as the M131 gene product, MCK1, it was 
soon determined that the transcript present during MCMV infection is a spliced 
product of M131 and M129, referred to as MCK2. The CC chemokine domain is 
confined to the region coded by MCK1 and is followed by a long carboxy-terminal 
domain with no known homology, making MCK2 considerably longer than other 
chemokines (MacDonald et al., 1999; MacDonald, Li, and Virgin, 1997).  
Initial studies in vitro showed MCK1 induced higher levels of Ca2+ 
mobilization in peritoneal exudates cells from mice infected with MCMV than cells 
from uninfected mice demonstrating MCK1 could activate cells recruited to the 
site of infection (Saederup et al., 1999). MCK2 was demonstrated to be important 
for viral spread within the host when a recombinant MCMV with mutations in the 
m131 gene showed a defect in dissemination. Mice infected with this mutant 
developed less inflammation at the site of inoculation, reduced secondary 
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viremia, as well as lower viral titers in the salivary glands, a site of dissemination 
following secondary viremia (Fleming et al., 1999; Saederup et al., 2001). This 
was the first direct evidence that a CMV encoded chemokine is important for the 
dissemination of the virus in its host. Additional work identified the cell type 
recruited by MCK2 as a late myeloid progenitor, consistent with reports that CMV 
infects and can remain latent in cells of the myelomonocytic lineage (Noda et al., 
2006). 
Rat CMV (RCMV) encodes a CC chemokine with similarity to both M131 
and M129, having N-terminal chemokine homology and a long carboxy-terminus 
like that of MCK2 (Vink, Beuken, and Bruggeman, 2000). Rats infected with 
RCMV deletion mutants lacking r131 had reduced viral loads in the spleen and 
salivary glands. Additionally these mice had reduced swelling and macrophage 
infiltration at the site of virus inoculation (Kaptein et al., 2004). Therefore, pr131 
appears to be a functional homolog of MCK2. 
Guinea pig CMV (GPCMV) has one gene with homology to CC 
chemokines, though it lacks positional or sequence similarity to the m131/m129 
genes of MCMV. GPCMV-MIP was most similar to the cellular chemokines, MIP-
1/ and HCC-1. GPCMV-MIP induced Ca2+ flux and migration of cells 
expressing HCCR-1 but did not elicit a response from cells expressing other CC 
receptors. HCC-1 is known to increase the proliferation of monocyte progenitors, 
a cell type infected by HCMV, and thus GPCMV-MIP is predicted to enhance the 
proliferation and/or recruitment of permissive cells consistent with the role of 
MCK2 (Haggerty and Schleiss, 2002). 
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Another -herpesvirus, human herpesvirus 6 (HHV-6), encodes a 
chemokine homolog, U83 (or vCCL4), which may facilitate viral dissemination in 
a manner similar to MCK2. U83 has a unique CX2CC motif but functions as a CC 
chemokine (French et al., 1999; Gompels et al., 1995). At least two HHV-6 
strains exist, HHV-6 variant A and HHV-6 variant B and each encodes a U83 
gene (U83A and U83B, respectively) (French et al., 1999). U83B is a selective 
CCR2 agonist, inducing calcium mobilization and chemotaxis of THP-1 cells and 
CCR2 transfectants albeit with lower activity than the cellular chemokine 
RANTES (Luttichau et al., 2003; Zou et al., 1999). This may be due in part to the 
extended N-terminus of U83B, which is associated with the reduced activity of 
some chemokine mutants (Fernandez and Lolis, 2002). HHV-6 replicates in CD4 
T cells and can establish latency in monocytes, both cells types that express 
CCR2 (Lusso et al., 1988). Therefore, U83 may recruit cells important for the 
establishment of acute and latent HHV-6 infection. In contrast, U83A induces flux 
in cells expressing a number of CC receptors making it the only known broadly 
acting CC agonist encoded by a virus. Interestingly, HHV-6A shows greater 
dissemination within the host than HHV-6B and it was suggested this might relate 
to the ability of U83A to interact with additional host cell types compared to U83B 
(Dewin, Catusse, and Gompels, 2006). 
Kaposi’s sarcoma-associated herpesvirus (KSHV) is a gamma 
herpesvirus responsible for the development of Kaposi’s sarcoma (KS), an 
endothelial cell-derived tumor that occurs in immunocompromised individuals. 
KSHV encodes three CC chemokine homologs, vCCL1, 2, and 3 (vMIP1-3). 
 29
vCCL1 and vCCL2 have similarity to CCL1 and  the more distantly related vCCL3 
is most similar to CCL11 (eotaxin) (Neipel, Albrecht, and Fleckenstein, 1997; 
Nicholas et al., 1997; Stine et al., 2000). While MCK2 enhances the inflammatory 
response to MCMV to facilitate viral dissemination, evidence suggests the KSHV 
chemokine homologs may contribute to viral pathogenesis by impairing the 
immune response to KSHV, thus interfering with its clearance. vCCL1 is an 
agonist of CCR8, a chemokine receptor expressed on TH2 cells, and stimulates 
Ca2+ flux of CCR8 expressing cell lines and isolated T cells (Dairaghi et al., 1999; 
Endres et al., 1999; Nicholas et al., 1997). vCCL3 functions via XCR1 and CCR4 
and can induce chemotaxis of TH2 cells, which differentially express CCR4 
(Luttichau et al., 2007). In contrast, vCCL3 is a poor chemoattractant of TH1 cells 
(Stine et al., 2000). Like the other KSHV chemokines, vCCL2 signals via 
receptors present on TH2 cells, CCR8 and CCR3 (Sozzani et al., 1998; Weber et 
al., 2001). However, vCCL2 is unique in that it also blocks receptors of all known 
chemokine classes, many of which are found on TH1 cells (Kledal et al., 1997). 
Consistent with a broadly acting antagonist, administration of vCCL2 impairs the 
recruitment of leukocytes in both the rat glomerulonephritis and lymphocytic 
choriomeningitis virus models of inflammation (Chen et al., 1998; Lindow et al., 
2003). Although vCCL1-3 have not been studied in animal models in the context 
of KSHV infection, collectively the data to date suggests these chemokines may 
alter the immune response to KSHV producing a TH2 polarized response that 
may be inefficient in clearing the virus. In fact, KSHV lesions expressing vCCL2 
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have a predominance of TH2 polarized cells compared to TH1 type cells based on 
cytokine profiles within the lesion (Weber et al., 2001). 
The KSHV chemokines may also contribute to KSHV pathology via other 
mechanisms. All three chemokines induce angiogenesis, a feature commons to 
KS. This may be due in part to their ability to chemoattract endothelial cells 
(Boshoff et al., 1997; Haque et al., 2001; Stine et al., 2000). Furthermore, vCCL1 
and 2 have anti-apoptotic effects in cell culture. Infected cells also exhibited 
higher levels of viral replication possibility due to the prolonged lifespan of the 
cells (Choi and Nicholas, 2008).  
In addition to herpesviruses, poxviruses also produce viral chemokines. 
Molloscum contagiosum virus (MCV) is a poxvirus that causes benign tumors in 
children as well as opportunistic infections in immunocompromised individuals. 
Interestingly, these lesions lack inflammatory infiltrates and it is thought virally 
encoded factors, such as the CC chemokine homolog, MC148, might contribute 
to the feature of these lesions. Sequence analysis predicted MC148 to be an 
antagonist because the N-terminus of the protein, a region important for receptor 
activation, is shorter compared to cellular CC chemokines. In vitro analysis 
confirmed this hypothesis. MC148 inhibits the migration of monocytes, 
lymphocytes, and neutrophils in response to a range of chemokines and was not 
an agonist for any CC or CXC receptor tested (Bugert et al., 1998; Damon, 
Murphy, and Moss, 1998). The number of receptors that MC148 antagonizes 
was narrowed to only CCR8 after further studies (Luttichau, Gerstoft, and 
Schwartz, 2001; Luttichau et al., 2000). In vivo analysis of MC148 is limited 
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because appropriate cell culture or animal models for the study of MCV are 
lacking. These examples show the wide range of viral chemokines that can affect 
the viral life cycle. 
 
Summary and Statement of Research Aims 
Due to the potential for serious outcomes in human cytomegalovirus 
infected newborns and immunocompromised individuals, the development of a 
CMV vaccine or other effective therapeutic treatment is desired.  In order to 
develop these treatments, a more complete understanding of CMV pathogenesis, 
including viral dissemination, is needed. CMV dissemination occurs via cell-
associated viremia in cells of hematopoietic origin including monocytes and 
neutrophils. However, the relative contribution of the different cell types to virus 
spread is not clearly defined. Furthermore, many CMVs encode chemokine 
homologs that alter the response of leukocytes during viral infection. The CC 
chemokines encoded by MCMV and RCMV, MCK2 and pr131 respectively, 
induce inflammatory responses that enhance virus dissemination to the salivary 
gland in vivo. The HCMV gene UL146 encodes a CXC chemokine, vCXCL-1, 
that functions comparably to CXCL8 in vitro. The analysis of this protein’s role in 
the context of HCMV infection is limited by the species specificity of the CMVs. 
Chimpanzee cytomegalovirus is the closest relative to HCMV and encodes a 
homolog of HCMV UL146, although their primary amino acid sequences vary. 
Nevertheless, CCMV may be an appropriate model for analyzing the function of 
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vCXCL-1 in vivo. Additionally, CCMV vCXCL-1 may be a functional homolog of 
the cytomegalovirus CC chemokines, such as MCK2, and facilitate dissemination 
of CCMV. The hypothesis of this study is that vCXCL-1CCMV is a functional CXC 
chemokine that contributes to viral dissemination. To test this hypothesis, the 
following research objectives were performed: 
1. Express CCMV vCXCL-1 and evaluate its function as a 
chemokine in vitro. 
2. Use MCMV as a surrogate to generate a recombinant MCMV 
expressing vCXCL-1CCMV to determine its ability to facilitate viral 
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Abstract 
Human cytomegaloviruses (HCMVs) are important pathogens in 
immunocompromised patients and newborns. The viral chemokine, vCXCL-1, of 
the Toledo (Tol) strain of HCMV has been implicated in HCMV virulence.  
Chimpanzee CMV (CCMV) has several genes with similarity to the vCXCL-1TOl 
gene, UL146.  In order to test whether the CCMV viral chemokine, vCXCL-1CCMV, 
is similar to vCXCL-1Tol, we characterized its function in vitro. Receptor binding, 
activation, chemotaxis, signaling, and apoptosis in neutrophils were compared 
between vCXCL-1Tol and vCXCL-1CCMV and host chemokines. Although the 
homologues have similar activation potentials, chemotactic properties, and 
signaling, vCXCL-1CCMV had a ~70-fold lower affinity for CXCR2 and displayed 
differences in integrin upregulation and neutrophil apoptosis.  These data 
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demonstrate that in spite of extensive amino acid variability in vCXCL-1, CCMV 




Human cytomegalovirus (HCMV) is a ubiquitous -herpesvirus, infecting 
between 50-90% of the population (Pass, 1985). Although asymptomatic in most 
cases, HCMV can cause serious complications in immunocompromised patients 
and newborns. Reactivation of latent HCMV or primary HCMV infection increases 
graft versus host disease (McCarthy et al., 1992), organ rejection in transplant 
patients (Ljungman, 1996), and inflammatory diseases such as gastroenteritis 
and retinitis in AIDS patients (Cheung and Teich, 1999). Congenital HCMV 
infection is the leading cause of infectious hearing loss in infants (Pass, 2001) 
and can lead to long-term sequelae such as learning disabilities and mental 
retardation. Due to the life-long effects associated with CMV congenital 
infections, the Institute of Medicine lists the development of a CMV vaccine as 
one of its top five priorities (Arvin et al., 2004).  In an effort to develop a safe and 
effective vaccine, a more thorough understanding of HCMV pathogenesis is 
needed. 
HCMV has a number of genes that encode proteins capable of 
suppressing or modulating the immune system that have been implicated in 
pathogenesis (Mocarski, 2002; Wiertz et al., 1997). Every aspect of the immune 
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response can be altered including class I and class II antigen processing and 
presentation as well as inflammatory responses (Mocarski, 2002). Proteins that 
alter immune responses likely contribute to HCMV’s pathogenesis.  Therefore 
understanding HCMV immune modulators may aid in designing safe and 
effective vaccines or potential antiviral therapeutics. 
The Toledo strain of HCMV, a strain that is known to cause disease in 
humans (Quinnan et al., 1984), was shown to produce a functional viral 
chemokine, vCXCL-1 (Penfold et al., 1999). Although chemokines are divided 
into four families, the majority of chemokines fall into the two families, CC and 
CXC chemokines, based on the spacing of their amino terminal cysteines. The 
CXC family has an additional amino acid between the two cysteines. The 
presence of a glutamate, leucine, arginine (ELR) motif amino terminal to the CXC 
residues further subclassifies the CXC chemokines into ELR-CXC or non-ELR 
families. The ELR-CXC family of chemokines was initially thought to function 
exclusively on neutrophils (Hebert, Vitangcol, and Baker, 1991) but also induce 
angiogenesis via endothelial cells (Addison et al., 2000; Coughlan et al., 2000; 
Strieter et al., 1995b). The vCXCL-1 protein is a member of the ELR-CXC 
chemokine family (Sparer et al., 2004). Indeed, vCXCL-1Tol (the subscript 
indicates the strain from which the protein is derived, e.g. Toledo) was shown to 
bind exclusively to CXCR2 and to induce calcium flux and chemotaxis of 
neutrophils (Penfold et al., 1999).  Penfold et al. speculated that the induction of 
neutrophils could be used as a means for viral dissemination, thus increasing 
virulence. In fact, HCMV can be isolated from neutrophils in 
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immunocompromised patients (Martin et al., 1984; Saltzman, Quirk, and Jordan, 
1988; van der Bij et al., 1988a) and neutrophilic infiltrates are found in AIDS 
patients who have CMV related retinitis (Holland et al., 1983; Pepose et al., 
1985). The UL146 gene, which produces the vCXCL-1 protein, is absent in an 
attenuated lab strain, AD169, and based on these findings, the vCXCL-1 protein 
has been hypothesized to be a potential virulence factor (Cha et al., 1996). 
Testing this hypothesis in vivo is limited by the species specificity of 
cytomegaloviruses. In this study we wished to further evaluate the effects of 
vCXCL-1Tol on neutrophil function in vitro and to compare those findings with host 
chemokines and a related chemokine from chimpanzee CMV (CCMV). 
vCXCL-1CCMV was chosen for comparison to vCXCL-1Tol to evaluate 
whether the conservative substitution in vCXCL-1CCMV’s ELR motif and variability 
in the N-loop region, both of which are considered important to receptor binding 
and triggering for host chemokines (Clark-Lewis et al., 1993; Clark-Lewis et al., 
1994; Lowman et al., 1996) affect protein function. In our work presented here, 
we compare differences in receptor binding affinity, cellular activation, signal 
transduction, chemotaxis, upregulation of adhesion molecules, and antiapoptotic 
functions, between vCXCL-1Tol, vCXCL-1CCMV, and host chemokines. 
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Materials and Methods 
Cells and Viral DNA  
SF9 insect cells were cultured in SF900 II media (Gibco) supplemented 
with 5% FBS, 2 mM L-glutamine, and 1% gentamicin (Biowhittaker). HiFive 
insect cells (Cellgro) were cultured in Insect Express media (Biowhittaker). 
Chimpanzee cytomegalovirus DNA was generously provided by Dr. Gary 
Hayward (Johns Hopkins School of Medicine).  
Sequence Analysis  
Amino acid sequence alignments of vCXCL-1Tol and vCXCL-1CCMV were 
performed using the clustalW algorithm of MegAlign sequence analysis software 
(DNASTAR). SignalP 3.0 (http://www.cbs.dtu.dk/services/SignalP/) was used to 
predict the signal sequence cleavage sites of vCXCL-1CCMV and vCXCL-1Tol. 
Protein Purification and Analysis  
The vCXCL-1 gene, UL146, was PCR amplified from either HCMV or 
CCMV viral DNA and cloned into the baculovirus transfer plasmid 1392 
(Invitrogen), which contains homologous regions for recombination into the 
baculovirus genome. PCR primers were designed to include the coding 
sequence for six histidines on the carboxyl terminus of the proteins for 
purification and Western blotting. SF9 cells were transfected with the plasmid 
construct and Sapphire linearized baculovirus DNA (Orbigen). Recombinant 
baculovirus containing the UL146 gene from either HCMV or CCMV was titered 
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and used to infect HiFive cells for optimum protein expression. Cells were 
harvested after 48 hours of incubation and protein was isolated from the 
supernatants using Ni-NTA agarose beads (Qiagen) and resuspended in PBS. 
Protein concentration was quantified using the Bradford assay (Biorad) according 
to the manufacturer’s instructions.  
N-terminal sequencing was used to verify cleavage of the signal peptide. 
100 pmol of vCXCL-1CCMV and vCXCL-1Tol was run on a 15% SDS-PAGE gel 
and then blotted onto PVDF membrane. The protein bands were excised from 
the membrane and analyzed by the Stanford PAN facility using de novo N-
terminal sequencing.   
Receptor Binding Analysis  
The ability of vCXCL-1CCMV and vCXCL-1Tol to compete for binding to 
CXCR2 was evaluated as previously described (Penfold et al., 1999). Briefly, 
HEK293 cell transfectants over-expressing CXCR2 were incubated with 125I- 
labeled CXCL1 and increasing concentrations of unlabeled chemokines. Cells 
were collected on glass filters, washed, and bound radioactivity was measured 
by liquid scintillation counting. 
Activation of Signal Transduction Pathways 
Differentiated HL-60 cells stably expressing CXCR2 were stimulated with 
different chemokines at 100nM for 1 min at room temperature and lysed in 2x 
RIPA buffer containing protease and phosphatase inhibitors (Walker et al., 2005). 
20 ug of total protein was then run on a 10% SDS PAGE and immunoblotted with 
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antibodies against phosphorylated Akt (Thr 308) (Cell Signal Technology), Akt, 
phosphorylated ERK, and ERK (Santa Cruz Biotechnology).   
Neutrophil Isolation  
Peripheral blood neutrophils (PBN) were isolated from EDTA-treated 
blood from healthy human volunteers using dextran sedimentation and density 
gradient centrifugation as previously described (Markert, Andrews, and Babior, 
1984). Erythrocytes were removed by hypotonic lysis. Neutrophils were 
resuspended in buffer or media as stated for the individual assays. Viable 
neutrophils were quantified by trypan blue exclusion. The use of human subjects 
has been approved by the University of Tennessee institutional review board 
(IRB# 6476B). 
Intracellular Calcium Mobilization Assays  
Release of calcium from intracellular stores was determined in freshly 
isolated PBN resuspended in PBS. Cells were loaded with 3g/ml Indo-1-AM 
(Molecular Probes) for 60 minutes at 37°C.  Cells were washed one time with 
PBS and diluted to 3-5 x 106 cells/ml in Hanks’ balanced salt solution (HBSS) 
containing Ca2+ and Mg2+ and 1% FBS. Chemokines were added at varying 
concentrations to 2 ml of cells. All host chemokines were purchased from 
Peprotech (Rocky Hill, NJ) and endotoxin levels were less than 0.1 ng per µg 
(1EU/µg).  Calcium release was measured using a Photon Technology 
International Spectrophotometer (New Jersey) at an excitation of 350 nm. 
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Relative intracellular calcium levels were expressed as the ratio of emissions at 
490 nm to the emissions at 400 nm (Sparer et al., 2004).  
PBN Migration Assays  
Migration assays were performed on human PBN resuspended in HBSS 
with 0.1% BSA and 10mM HEPES. Assays were performed in triplicate in 96-well 
chemotaxis plates. 20 l of chemokines were loaded at varying concentrations 
into the lower well of the modified Boyden chamber (Neuroprobe) and fitted with 
a 5M filter. 1x106 PBN in 30 l were added to the upper well. The cells were 
incubated for 3 hr at 37°C. Migration of PBN was measured by direct count of 
cells that had migrated through the filter into the lower chamber. The chemotactic 
index was calculated as the number of cells that migrated in the presence of 
chemokine divided by the number of cells that migrated due to buffer only.  
Apoptosis Assays  
PBN were resuspended in RPMI-1640 (Biowhittaker) with 1% FBS and 
added to a 96-well plate at 1x106 cells/well. Chemokines were added to the wells 
at a final concentration of 100 nM. Plates were incubated at 37°C, 5% CO2 for 24 
hrs. Cells were labeled with AnnexinV and propidium iodide (PI) using the 
Annexin V Kit (Caltag) according to the manufacturer’s instructions. Cells were 




CD11 Staining  
PBN were resuspended in RPMI-1640 (Biowhittaker) with 1% FBS and 
added to a 96-well plate at 1x106 cells/well. PBN were exposed to 100 nM of 
chemokines for 2 hr at 37°C and 5% CO2. Cells were washed with PBS and 
blocked with 1% goat serum. PBN were incubated with fluorescently conjugated 
CD11a, CD11b, and CD11c antibodies (Caltag) on ice and fixed with 4% 
paraformaldehyde. Cells were analyzed by flow cytometry. 
 
Results 
Comparison of amino acid sequences.   
Sequence analysis indicates vCXCL-1CCMV has limited homology to 
vCXCL-1Tol, CXCL1, and CXCL8 (Figure 2). Although the amino acid sequences 
show relatively low homology, all share important characteristics of CXC 
chemokines, including an N terminal signal peptide, spacing of the four 
conserved cysteines, and an ELR like motif. The ELR-CXC motif is present in all 
CXC chemokines that bind CXCR1 and CXCR2.  While the vCXCL-1 from 
clinical isolates sequenced previously display conservation of this ELR-CXC 
motif (Arav-Boger, Zong, and Foster, 2005; Lurain et al., 2006; Prichard et al., 
2001), it is modified in vCXCL-1CCMV with an LM conservative substitution. 
Even though this is a conservative substitution, this replacement could affect 
neutrophil function based on published results showing that host chemokines 














Figure 2. Amino acid alignment of the mature forms of CXCL1, CXCL8, vCXCL-
1CCMV, and vCXCL-1Tol. Residues that are 100% conserved are indicated above 
the alignment. The N-loop region is residues 10-20. vCXCL-1CCMV is 22% 
identical and 52% similar to vCXCL-1Tol, 17% identical and 33% similar to 







calcium mobilization (Clark-Lewis et al., 1993; Hebert, Vitangcol, and Baker, 
1991). Overall, the vCXCL-1Tol and vCXCL-1CCMV proteins are 52% similar with 
only 22% identity. This observation mirrors the low identity previously observed in 
the sampling of human clinical isolates, suggesting that only core, conserved 
regions of the protein are required for functionality. The N-loop region is another 
domain that is important for receptor engagement and function. This region lies 
between the second cysteine and the 310 helix usually from amino acids 10-20 
(Fernandez and Lolis, 2002). Only a conserved proline residue within the N loop 
is conserved between the two proteins (Figure 2).  These differences in primary 
amino acid sequence may have pleiotropic effects.  Alterations in these domains 
may lead to differences in affinity that subsequently alter binding and/or function.  
We set out to determine whether the variability within vCXCL-1CCMV results in 
differences in function. 
vCXCL-1 proteins can be produced and purified using the baculovirus 
expression system.  
In order to address functional differences between host and viral 
chemokines, we generated both proteins using recombinant baculovirus.  We 
chose this system because baculovirus expression systems utilize the 
mammalian signal peptidase cleavage site and generate eukaryotic glycosylation 
patterns and folding. Following infection of HiFive cells with recombinant 
baculovirus expressing the His-tagged viral chemokines, the secreted protein 
was purified using Ni-NTA agarose beads. A silver stain of the isolated proteins 
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indicates the high purity achieved in the isolation procedure (Figure 3A). The 
apparent size of both vCXCL-1CCMV and vCXCL-1Tol at approximately 14 kDa is 
larger than the predicted 10 kDa.  The differences in molecular weight were due 
to glycosylations (both have two predicted N-linked glycosylation sites) as 
subsequent digestion with the glycosidase, PNGase F, generated proteins of the 
predicted size (10 kDa) (data not shown). Mass mapping of trypsin-digested 
vCXCL-1CCMV and vCXCL-1Tol proteins confirmed the identities of the isolated 
proteins (data not shown). N-terminal sequencing confirmed proper cleavage of 
the signal peptide (Figure 3B).  Proper cleavage of the signal sequence is critical 
for chemokine function (Clark-Lewis et al., 1991). In fact, alteration by the 
addition or deletion of a single amino acid has been shown to abrogate the 
function of some chemokines (Proudfoot et al., 1999; Proudfoot et al., 1996). N-
terminal sequencing indicated the signal peptide of vCXCL-1CCMV was cleaved at 
the threonine residue directly preceding the EMR-CXC motif as predicted by the 
SignalP program (Figure 3B). Of the two possible cleavage sites predicted for 
vCXCL-1Tol cleavage occurred at the threonine residue (T23) corresponding to 
that of vCXCL-1CCMV. Our data show that the T23 site is the preferential cleavage 
site.  A synthetic vCXCL-1Tol based on the other signal sequence cleavage site 
(Y18) was previously shown to be 100-fold less active than that cleaved at the 
threonine residue corresponding to the N terminus in our preparations (Penfold et 
al., 1999). This is the first confirmation that this cleavage site is used for naturally 
processed vCXCL-1Tol indicating that the active form of the protein is 
preferentially synthesized.  






















Figure 3. vCXCL-1 protein production. A) vCXCL-1CCMV and vCXCL-1Tol 
production in baculovirus. 1 mg of 6His-tagged protein eluted from nickel beads 
was run on a 15% SDS PAGE gel and silver-stained. B) N-terminal sequencing 
confirmed the predicted cleavage of the signal peptide of vCXCL-1CCMV and 
vCXCL-1Tol. 
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vCXCL-1CCMV induces intracellular calcium release in PBN.  
With the differences noted in primary amino acid sequence, we assessed 
whether these differences correlate with differential functions. The release of 
intracellular calcium is often used as an indicator of chemokine induction of 
cellular activation (Murphy, 2003). We examined the ability of vCXCL-1CCMV to 
induce intracellular calcium mobilization in freshly isolated PBN. The dose 
response analyses of vCXCL-1CCMV and vCXCL-1Tol showed similar activation 
potential (Figure 4), demonstrating that the amino acid differences did not alter 
triggering of intracellular calcium release.   
Previous work demonstrated the ability of vCXCL-1Tol to desensitize PBN 
activation following exposure to a number of human chemokines, including 
CXCL1 (Penfold et al., 1999). Receptor desensitization is determined by the 
receptor affinity for the chemokine, phosphorylation of the carboxyl terminus, and 
subsequent  arrestin binding. We confirmed the ability of vCXCL-1Tol to 
desensitize PBNs to CXCL1 activation. However, CXCL1 is not able to 
completely desensitize to vCXCL-1Tol (Figure 5A).  
The desensitization profile of vCXCL-1CCMV (Figure 5B) was compared to 
that of vCXCL-1Tol. Unlike vCXCL-1Tol, vCXCL-1CCMV is unable to completely 
desensitize PBN to activation via CXCL1.  In addition CXCL1 is able to 
completely desensitize to vCXCL-1CCMV added to PBN following CXCL1. Because 
CXCL1 binds only to CXCR2, its ability to inhibit vCXCL-1CCMV calcium 
mobilization suggests that vCXCL-1CCMV, like vCXCL-1Tol, binds via CXCR2. 














Figure 4. vCXCL-1CCMV has a similar activation threshold as vCXCL-1Tol and can 
be desensitized by CXCL1. Changes in fluorescence were measured over time 
after exposure of human PBN to different concentrations of vCXCL-1CCMV or 
























Figure 5. Desensitization profile of vCXCL-1Tol /CXCL1 (A.) and  (B.) vCXCL-
1CCMV /CXCL1. 100nM of CXCL1, vCXCL-1CCMV, or CCL5 were added at the 
times indicated by the arrow.  A second addition of 100nM of the indicated 
chemokine was added at 90 seconds.   Changes in fluorescence were measured 








vCXCL-1CCMV resulted in minimal calcium mobilization further indicating that 
vCXCL-1CCMV functions via CXCR2 (data not shown). The incomplete 
desensitization to CXCL1 is likely due to a lower affinity of human CXCR2 
(hCXCR2) for vCXCL-1CCMV.  Alternatively, a reduced ability of vCXCL-1CCMV to 
initiate phosphorylation of CXCR2 to the same degree as vCXCL-1Tol could result 
in lower levels of receptor desensitization (Richardson et al., 2003). These 
results indicate that vCXCL-1Tol engages hCXCR2 differently than vCXCL-1CCMV 
such that different desensitization patterns are triggered. 
vCXCL-1CCMV has reduced affinity for CXCR2 compared to vCXCL-1Tol or 
CXCL1.  
The ability of CXCL1 to desensitize to vCXCL-1CCMV in the calcium 
mobilization assays suggests this viral chemokine binds to CXCR2. However, the 
lack of complete desensitization when vCXCL-1CCMV was used to desensitize 
against CXCL1 could reflect differences in receptor binding affinity for the viral 
chemokine. To test this possibility, competition-binding assays were used to 
evaluate the ability of vCXCL-1CCMV to compete for binding to CXCR2.   vCXCL-
1CCMV was able to compete with 
125I CXCL1 for binding to hCXCR2, albeit at a 
higher 50% inhibitory concentration (IC50) than that required for CXCL1 or 
vCXCL-1Tol (Figure 6). We conclude that vCXCL-1CCMV binds to hCXCR2 but with 
a lower affinity than vCXCL-1Tol (vCXCL-1Tol IC50 = 0.9 nM versus vCXCL-1CCMV 
IC50=65 nM) and this may explain the differences in desensitization patterns seen 
















Figure 6. vCXCL-1CCMV binds with less affinity than vCXCL-1Tol to CXCR2. 293 
cells stably expressing only CXCR2 were incubated with a constant amount of 
125I-CXCL1 and increasing amounts of unlabeled chemokines. Calculated IC50 
values are indicated in molar concentrations in parentheses.  Data is 






while vCXCL-1CCMV cannot desensitize to exposure to CXCL1).  Affinity may not 
be the sole explanation for the differences between vCXCL-1Tol desensitization 
patterns with CXCL1 (Fig. 3B), yet no differences in the calcium flux activation 
potentials of vCXCL-1CCMV and vCXCL-1Tol were seen (Fig. 4).   The viral 
chemokines could be engaging the receptors differently such that  arrestins are 
not activated as efficiently.  This would explain the differences in desensitization 
patterns while not affecting the activation potentials. 
vCXCL-1CCMV induces migration of human neutrophils.  
An important function of chemokines is their ability to induce chemotaxis 
of a variety of cells. ELR-CXC chemokines and vCXCL-1Tol trigger migration of 
neutrophils (Penfold et al., 1999). We tested the ability of vCXCL-1CCMV to induce 
migration of human PBN using a modified Boyden chamber. vCXCL-1CCMV 
induces migration of neutrophils with equal potency as the host chemokine,  
CXCL1 (Figure 7).   Therefore, vCXCL-1CCMV chemoattracts PBNs efficiently in 
spite of differences with vCXCL-1Tol in affinity for hCXCR2 and primary amino 
acid sequences. 
vCXCL-1CCMV activates ERK and Akt signaling pathways.  
The differences in affinity between the chemokines may affect functional 
activation (Clark-Lewis et al., 1994; Clark-Lewis et al., 1991; Geiser et al., 1993; 
Wu et al., 1996) as we observed with the receptor desensitization patterns 
(Figure 5).  Upon CXCR2 binding, G protein signal transduction cascades are 















Figure 7. vCXCL-1CCMV induces migration of neutrophils. Migration assays were 
performed by loading human PBN onto the upper chamber of a 96-well plated 
fitted with a 5mm filter with increasing amounts of chemokine loaded in the lower 
chamber. Results are reported as a chemotactic index of the number of cells 







transduction cascades activated upon CXCL1 binding to CXCR2 are the 
extracellular signal-related protein kinase (ERK), a member of the mitogen-
activated protein (MAP) kinase family (Shyamala and Khoja, 1998) and protein 
kinase B/Akt pathway, which is activated via the phophoinositide-3 kinase 
signaling cascade. The activation of the ERK and Akt signaling pathways are 
triggered following exposure to chemokines and -arrestin activation (Lefkowitz 
and Shenoy, 2005). In order to assess whether the differences in binding to 
CXCR2 induce different signaling cascades, we analyzed the activation profile of 
differentiated HL-60 cells stably expressing CXCR2 following exposure to 
vCXCL-1CCMV. HL60s were used due to the difficulty of isolating fresh PBNs 
without inadvertent signal transduction activation and because of host-to-host 
variation. Exposure of differentiated HL-60 cells to vCXCL-1CCMV and vCXCL-1Tol 
resulted in phosphorylation of both ERK and Akt to similar levels as the CXCL8 
and CXCL1 controls (Figure 8).   At least for these two important signaling 
pathways, the affinity for hCXCR2 does not markedly impact activation. 
vCXCL-1CCMV upregulates CD11b and CD11c on the surface of PBN. 
 2 integrins, including CD11a, CD11b, and CD11c, are membrane bound 
receptors present on leukocytes that are necessary for PBN adhesion to and 
migration across the endothelium (Mayadas and Cullere, 2005). Because of their 
potential importance in recruitment of PBN to the site of CMV infection, we tested 
the ability of vCXCL-1CCMV and vCXCL-1Tol to alter surface expression of these 













Figure 8. Both viral and host chemokines activate the ERK and Akt pathways. 
Differentiated HL-60 cells stably expressing CXCR2 were stimulated with 100nM 
chemokine for 1 min at room temperature and lysed instantly. Lysates were 
immunoblotted using antibodies against the phosphorylated (p) and 








resulted in no change in the levels of CD11a expressed on the cell surface 
(Figure 9). However, CD11b and CD11c levels increased upon exposure to 
vCXCL-1CCMV (30% and 12% above control respectively) and to similar levels as 
CXCL1 (51% and 11%) (Figure 9). Interestingly, vCXCL-1Tol also increased 
expression of these proteins on PBN but to somewhat higher levels (106% and 
36%) compared to CXCL1 or vCXCL-1CCMV. PBN exposed to CXCL8 showed 
similar levels of CD11b/c expression (106% and 46%) as those exposed to 
vCXCL-1Tol.  These results imply that the two viral chemokines differentially 
induce adhesion molecule upregulation:  vCXCL-1Tol is similar to CXCL8 
stimulation and vCXCL-1CCMV is similar to CXCL1.  These data show that amino 
acid differences between these chemokines can lead to different activation 
profiles on PBN that could affect their functions in vivo.   
vCXCL-1CCMV decreases apoptosis of human PBN.  
PBN normally undergo apoptosis in 24-48 hours (Haslett, 1992). Because 
PBN play a role in the dissemination of HCMV (Gerna et al., 2000; Gerna et al., 
1992), HCMV may have evolved viral chemokines that alter PBN viability. We 
assessed the capacity of vCXCL-1CCMV and vCXCL-1Tol to alter apoptosis of 
PBN. We found that vCXCL-1CCMV and vCXCL-1Tol decreased apoptosis (17% 
vs. 29% respectively) (Figure 10).  This decrease was similar to CXCL1 (21%). 
However, it was not as great as the reduction following exposure to CXCL8 
(44%). Any differences in the longevity of neutrophils could affect viral survival or 














Figure 9. vCXCL-1Tol and vCXCL-1CCMV differentially increase CD11b and CD11c 
expression on the surface of neutrophils. Human PBN were incubated in the 
presence of 100nM of different chemokines (vCXCL-1Tol, vCXCL-1CCMV, CXCL1, 
or CXCL8) and labeled with fluorescently-conjugated antibodies against CD11a, 
CD11b, and CD11c.  The table summarizes the flow cytometry data and is 
expressed as percent change in the mean fluorescent intensity compared to non-





















Figure 10. vCXCL-1CCMV and vCXCL-1Tol reduce apoptosis in neutrophils. Human 
PBN were incubated for 24 hrs in the presence of either viral or human 
chemokines (100nM).  After incubation, cells were labeled with annexin-FITC and 
propidium iodide and then analyzed by flowcytometry. The percent reduction in 
apoptosis relative to the non-stimulated cells is summarized in the table.  This is 




The significant findings of this paper are that two distantly related viral 
chemokines (vCXCL-1Tol and vCXCL-1CCMV) have similar functions in spite of 
distinct differences in affinity for CXCR2 and amino acid composition in the N 
loop and ELR motifs.  These regions of host chemokines have been shown to 
play a role in receptor binding and activation (Clark-Lewis et al., 1993; Fernandez 
and Lolis, 2002; Hebert, Vitangcol, and Baker, 1991).  Although vCXCL-1CCMV 
was able to bind CXCR2, it was not able to bind with as high of an affinity as 
vCXCL-1Tol or CXCL1 in competition binding studies (Figure 6). This difference 
could reflect the difference in affinity of vCXCL-1CCMV for human CXCR2 versus 
chimpanzee CXCR2 in these assays. However, the CXCR2 receptor in these two 
species is highly conserved. Chimpanzee CXCR2 is 99% identical to human 
CXCR2 based on amino acid comparisons. Only 2 amino acids out of 355 are 
different. These two amino acids are located in transmembrane regions 5 and 7 
(Alvarez et al., 1996). Importantly, the transmembrane regions of CXCR2 that are 
known to be important for receptor structure are conserved between the human 
and chimpanzee receptors (Baggiolini, Dewald, and Moser, 1997). It is possible 
that binding motifs and structural differences not yet identified could result in 
differential binding of vCXCL-1CCMV to hCXCR2, although this seems unlikely. 
It is perhaps more likely that differences in the viral chemokines 
themselves are responsible for the differences in binding affinity. This may be 
due in part to the mutated ELR motif (LM) present in vCXCL-1CCMV. The ELR 
motif is known to be important in receptor binding and signaling (Clark-Lewis et 
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al., 1991; Schraufstatter et al., 1993). Mutagenesis of each of the ELR residues 
of CXCL8 reduced the ability of CXCL8 to competitively bind to neutrophils and 
CXCR2 expressing cell lines (Hebert, Vitangcol, and Baker, 1991). However, 
these mutations did not completely eliminate receptor binding and other regions, 
such as the N-loop region, are also important in receptor binding (Fernandez and 
Lolis, 2002). vCXCL-1CCMV only shares the single amino acid, proline, with 
CXCL1 in this region and the sequence diversity in this region may contribute to 
the differences seen in binding affinity. Additionally, the presence of a glycine at 
residue 31 has been shown to be important for receptor binding (Clark-Lewis et 
al., 1994; Clark-Lewis et al., 1995; Li et al., 2002). vCXCL-1C956 from a clinical 
isolate of HCMV has a substitution at the G31 residue but shows equivalent 
binding to CXCR2 and an equal capacity for inducing calcium mobilization to 
levels comparable to CXCL1 (unpublished data). This data demonstrates that a 
substitution at this residue is not solely responsible for the lower binding affinity 
of vCXCL-1CCMV to CXCR2. Finally, the carboxyl terminus plays some role in the 
function of chemokines. Although not thought to be important in all cases, the 
carboxyl terminal region of CXCL1 has been implicated in receptor binding (Roby 
and Page, 1995). The C-terminal region of the viral chemokines is considerably 
longer than that of CXCL1 and CXCL8 and may contribute to differential binding 
or signaling of the receptor (Figure 2 and (Penfold et al., 1999)).  
Evolution has directed the variation of HCMV genes such that viral genes 
have similar functions with limited homology to host genes.  As discussed above, 
vCXCL-1 shows sequence variation from its cellular counterpart, CXCL1. 
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Additionally, sequencing of human CMV clinical isolates has revealed extreme 
sequence variability between strains, with only limited regions of conservation 
and identities below 30% (Arav-Boger et al., 2006b; Prichard et al., 2001). 
Similarly UL144, a viral tumor necrosis factor (TNF)-alpha-like receptor gene, 
displays high variance in its sequence between clinical strains and correlates 
with severity of congenital disease (Arav-Boger et al., 2006a; Arav-Boger and 
Pass, 2002). Both human and rhesus CMVs encode interleukin 10 homologs, 
which retain functionality despite a sequence identity of less than 30% to their 
cellular counterparts (Kotenko et al., 2000; Spencer et al., 2002). Such variability 
among secreted and surface-displayed proteins may be driven by selective 
immune pressures, although why certain genes appear more susceptible to 
these pressures than others is unknown. 
An important question is whether the reduced binding affinity by vCXCL-
1CCMV results in differences in the functional capacity of this protein. Relative 
differences in activity between CXCL8 and vCXCL-1CCMV can be difficult to 
assess based on the ability of CXCL8 to bind and signal via both CXCR1 and 
CXCR2, whereas vCXCL-1CCMV, based on our data, only activates CXCR2. 
Therefore, we also compared the biological activity of vCXCL-1CCMV to the 
CXCR2-specific chemokine, CXCL1. As we have shown, vCXCL-1CCMV induces 
activity in most biological assays comparable to that of CXCL1. Given the lower 
binding affinity of vCXCL-1CCMV, we also tested the activation profile of vCXCL-
1CCMV at 1M, which is fifteen fold above the IC50, to ensure complete saturation 
of all expressed receptors.  However, the higher concentration of vCXCL-1CCMV 
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did not result in a greater calcium flux than at 100nM, therefore it is reasonable to 
assume that the receptors were saturated at the 100nM concentration used in 
these experiments. This leads us to conclude that lower receptor binding affinity 
does not correlate with a reduction in biological activity when compared with 
CXCL1. One exception where reduced binding affinity may be important is the 
ability of vCXCL-1CCMV to completely desensitize neutrophils upon subsequent 
exposure to CXCL1. In this case, the ability of CXCL1 to compete more 
effectively (i.e. higher binding affinity) for binding to CXCR2 allows it to displace 
vCXCL-1CCMV and induce a second wave of calcium mobilization. Interestingly, 
vCXCL-1CCMV was unable to desensitize PBN to CXCL1 even when used at a 10-
fold higher concentration compared to CXCL1 (data not shown) suggesting the 
lack of complete desensitization may be due in part to differential activation and 
phosphorylation of CXCR2. Phosphorylation of G protein-coupled receptors 
prevents reassociation of the G protein and the receptor, resulting in a receptor 
that is desensitized to further stimulation by ligand (Neel et al., 2005). 
vCXCL-1Tol was previously found to function via CXCR2, inducing calcium 
mobilization and chemotaxis of PBN with a potency comparable to CXCL8 
(Penfold et al., 1999). We have verified similar findings for the CCMV viral 
chemokine, vCXCL-1CCMV. vCXCL-1CCMV showed a similar profile of calcium 
mobilization as vCXCL-1Tol at the concentrations tested. Additionally, vCXCL-
1CCMV was able to induce migration of neutrophils as effectively as CXCL1. The 
ability of vCXCL-1CCMV to induce PBN chemotaxis could enable the virus to 
modulate the immune response to benefit viral survival or dissemination. An 
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example of a viral chemokine that functions in viral dissemination is the MCK2 
chemokine from murine cytomegalovirus (MCMV) (Fleming et al., 1999; 
Saederup et al., 2001; Saederup et al., 1999). Infection of mice with MCMV 
lacking the MCK chemokine gene resulted in decreased inflammation at the site 
of infection and dissemination of the virus. This evidence illustrates the ability of 
viral chemokines to alter the immune response in vivo (Saederup et al., 2001). 
Although these chemokines are from two different chemokine families (CXC for 
vCXCL-1CCMV and CC for MCK2), they could be functional homologues. This is a 
common theme for CMVs.  Other immune modulatory proteins such as the class 
I down regulating proteins from the M152 gene in MCMV (Ziegler et al., 1997) 
and the US2, US3, and US11 genes in HCMV (Gewurz et al., 2001a; Landolfo et 
al., 2003; Rehm et al., 2002) lack sequence homology yet both viruses achieve 
the same end result of down-regulation of antigen presentation.  
Chemotaxis of circulating neutrophils is dependent on adhesion to and 
extravasation across the endothelium. This process can be mediated by the 
interaction of 2 integrins present on the surface of PBN with their ligands on 
endothelial cells. The 2 integrin family includes CD11a, CD11b, CD11c, and 
CD11d. Previous studies demonstrated the ability of the chemokines, CXCL8 
and CXCL1, to upregulate CD11b expression (Detmers et al., 1990). Here we 
demonstrate that both vCXCL-1CCMV and vCXCL-1Tol increase CD11b and CD11c 
expression on the cell surface. Furthermore, CXCL8 upregulation of CD11b on 
PBN involves the ERK signaling pathway (Takami, Terry, and Petruzzelli, 2002), 
which was shown to be upregulated by both viral chemokines (Figure 8). 
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Therefore, these viral chemokines could enhance the ability of PBN to adhere to 
and cross the endothelium allowing migration of neutrophils through the tissue to 
the site of infection. 
Regulation of apoptosis of neutrophils could also provide an advantage to 
HCMV by allowing PBN to survive and disseminate HCMV.  In fact HCMV 
produces several proteins that alter apoptosis in infected cells (McCormick et al., 
2005; Smith and Mocarski, 2005).  Our results show that vCXCL-1CCMV, vCXCL-
1Tol, and CXCL1 reduce apoptosis to similar levels. CXCL8 shows the highest 
reduction in apoptosis however this chemokine has also been shown to alter 
apoptosis primarily via CXCR1 (Glynn, Henney, and Hall, 2002) through 
activation of the ERK and Akt pathways in neutrophils (Akgul, Moulding, and 
Edwards, 2001; Khreiss et al., 2004). The similarity in vCXCL-1CCMV and vCXCL-
1Tol activation of the ERK and Akt pathways suggests that other pathways must 
also be involved. Prolonging PBN survival would be advantageous for HCMV. 
The longer the neutrophil is viable the greater the chance it will be used for 
dissemination (Grundy et al., 1998). 
In conclusion, we have shown that the CCMV viral chemokine has similar 
biological activities to vCXCL-1Tol and CXCL1 except for integrin upregulation 
and inhibition of apoptosis. This is in spite of differences in binding affinities and 
amino acid variability in the N-loop region and ELR motif.  A similar example is 
found in human herpesvirus 8 (HHV8) viral chemokines vMIP I and vMIP II 
(Boshoff et al., 1997; Kledal et al., 1997).  Both chemokines have limited 
homology (38% and 41% respectively) to host chemokines CCL2 (MIP1) and 
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CCL5 (RANTES) (Fernandez et al., 2000).  These chemokines have similar 
functions to host chemokines yet can act as antagonists and bind to additional 
host chemokine receptors.  Although we have not found antagonistic functions 
for vCXCL-1s, vMIP II is yet another example of a herpesvirus evolving a 
chemokine with unique functions.   
We can infer from our data that very simple structural motifs guide 
receptor binding and activation rather than specific amino acid-to-amino acid 
interactions.  The eotaxin family of host chemokines provides a similar example.  
These chemokines also have considerable variability yet slight differences in 
binding and activation (Forssmann et al., 1997; Kitaura et al., 1999; Shinkai et 
al., 1999; White et al., 1997).  All eotaxins bind and/or activate the same eotaxin 
receptor, CCR3, in spite of very little amino acid identity (Duchesnes et al., 
2006). There is some variability in the responses to the different eotaxins leading 
to speculation that these proteins may exist to “fine-tune” their interaction with 
their receptor to produce different biological outcomes. We propose that the 
variability in the viral chemokines helps to fine tune the neutrophil response, 
which allows for more efficient HCMV dissemination.  This explains the high 
degree of variability that occurs naturally in HCMV isolates (He et al., 2006) and 
between their homologous host chemokines.  The vCXCL-1s from different 
strains of HCMVs could allow for increased dissemination via find tuned 
alterations of apoptosis and integrin expression that provides a survival 
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Many CMVs encode viral homologs of chemokines that may be involved in 
viral dissemination. The virulent HCMV lab strain, Toledo, produces a functional 
CXC chemokine, vCXCL-1Tol. The species specificity of the CMVs limits analysis 
of this protein’s role in vivo. The closely related chimpanzee cytomegalovirus 
produces the related homolog, vCXCL-1CCMV, with similar in vitro function. The in 
vivo function of vCXCL-1CCMV may correlate with its HCMV homolog and CCMV 
may be a valuable non-human primate system for these studies. MCMV is a well-
established model of CMV pathogenesis and dissemination and was chosen to 
initially characteize vCXCL-1CCMV. We generated the recombinant MCMV, 
RMvCXCL-1CCMV, to assess the role of vCXCL-1CCMV in virus dissemination in 
vivo. RMvCXCL-1CCMV had similar 1 dissemination as the parental strain, 
RM4511, but was not detected in the salivary gland following 2 dissemination. 
This was not due to clearance of RMvCXCL-1CCMV by the adaptive immune 
response or neutrophils of innate immunity. Our data suggest RMvCXCL-1CCMV 
likely has a defect in dissemination to the salivary gland possibly due to 
overexpression of vCXCL-1CCMV. 
Introduction 
Human cytomegalovirus (HCMV) is a -herpesvirus that infects between 
50% and 90% of the population resulting in largely asymptomatic infections 
(Pass, 1985). However, HCMV can cause serious complications in 
immunocompromised individuals and newborns (Pass, 2001). Primary or 
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reactivated HCMV is a frequent cause of retinitis in AIDS patients (Cheung and 
Teich, 1999) and increases the incidence of organ rejection and graft versus host 
disease in transplant recipients (Ljungman, 1996; McCarthy et al., 1992). Central 
nervous system damage due to congenital HCMV infection affects between 5000 
and 8000 newborns in the U.S. each year (Adler, 2005). As a result, HCMV is the 
leading cause of infectious hearing loss and non-hereditary mental retardation 
(Pass, 2001). Due to the long-term morbidity associated with CMV congenital 
infections, the Institute of Medicine lists the development of a CMV vaccine as a 
top priority (Arvin et al., 2004). 
Understanding HCMV pathogenesis is important for the development of 
an effective vaccine or novel therapeutics. However, CMV pathogenesis is 
complex. CMVs encode numerous proteins that modulate or suppress the host 
immune system. CMV can inhibit apoptosis of infected cells, impair antigen 
processing, and alter the inflammatory response including the chemokine 
network (Mocarski, 2002). Chemokines are small, chemotactic cytokines that are 
important for leukocyte trafficking and activation. Chemokines are divided into 
four groups (CC, CXC, CX3C, C) based on the spacing of their amino terminal 
cysteines although most chemokines are members of either the CC or CXC 
class. These chemokines attract and activate a variety of immune cells 
responsible for viral clearance and contribute to CMV pathogenesis (Benedict et 
al., 2006; Cavanaugh et al., 2003).   
Not only does HMCV infection alter the expression of host chemokines 
(Chan et al., 2008) but many CMVs also encode viral homologs of chemokines 
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and their receptors (van Cleef et al., 2006). The Toledo strain of HCMV, a 
virulent lab strain (Quinnan et al., 1984), produces a functional CXC chemokine, 
vCXCL-1Tol. vCXCL-1Tol was found to bind the chemokine receptor CXCR2 
inducing chemotaxis and calcium flux in neutrophils (Penfold et al., 1999). 
Chimpanzee cytomegalovirus, a close relative of HCMV, encodes a homolog of 
vCXCL-1Tol. Recently, we have shown that vCXCL-1CCMV also triggers calcium 
release and chemotaxis of neutrophils.  Both HCMV and CCMV vCXCL-1 
upregulate adhesion molecule expression on neutrophils and downregulate 
neutrophil apoptosis, albeit with different potencies (Miller-Kittrell et al., 2007). 
These findings provide circumstantial evidence for the role of vCXCL-1 in the 
activation and recruitment of neutrophils for CMV dissemination. Neutrophils 
have been shown to be important in HCMV dissemination in vivo. HCMV can be 
recovered from neutrophils of immunocompromised patients (Saltzman, Quirk, 
and Jordan, 1988; van der Bij et al., 1988b) and neutrophilic infiltrates are 
present in CMV associated retinitis of AIDS patients (Holland et al., 1983; 
Pepose et al., 1985). Strict species specificity of the CMVs limits the direct 
evaluation of vCXCL-1 in HCMV dissemination. The function of vCXCL-1CCMV 
may correlate with its HCMV homolog, although in vivo characterization of this 
protein is complicated by the current lack of a chimpanzee model of CMV 
infection. 
MCMV is a well-established animal model of CMV infection and has 
similar cell tropism and disease manifestations as HCMV (Hudson, 1979). MCMV 
expresses a chemokine homolog, MCK2, which has been shown to increase the 
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inflammatory response in mice and enhance dissemination of MCMV to the 
salivary gland (Fleming et al., 1999; Saederup et al., 2001). Therefore, MCMV 
was chosen to initially characterize vCXCL-1CCMV in vivo. Because CCMV does 
not infect mice, we generated a recombinant MCMV expressing vCXCL-1CCMV in 
order to assess the role of the CCMV viral chemokine in virus dissemination in 
vivo. 
 
Materials and Methods 
Cells and Viruses   
Murine NIH3T3 and M210B4 cells (ATCC) were propagated in DMEM 
supplemented with 10% Fetalclone III (Hyclone), 1% penicillin/streptomycin, 1X 
NEAA, 1% sodium pyruvate (100mM), and 0.5 % Hepes (1M). The parental 
MCMV strain used in this study was MCMV RM4511 which has a 1.7 kb 
puromycin-green fluorescent protein (GFP) cassette inserted into the IE2 region 
and a double point mutation in the m131 gene resulting in a nonfunctional MCK2 
protein (Figure 11) (Saederup et al., 2001). 
Mice  
3-4 week old Balb/c and SCID/NCr mice were purchased from Jackson 
Laboratory (Bar Harbor, ME) or Taconic Labs, respectively. hCXCR2 transgenic 






Figure 11. Schematic Representation of Wild Type (WT) MCMV, Parental MCMV 
(RM4511), RMmCXCL1, and RMvCXCL1CCMV. K181, a wild type strain of MCMV, 
contains the endogenous murine viral chemokine gene, mck. The RM4511 
recombinant MCMV contains a double point mutation resulting in a missense 
mutation that converts amino acids CC to GR.  This in effect creates an MCK2 
negative strain. Additionally, a green fluorescent protein (GFP)/puromycin 
expression cassette was inserted into the ie2 region. The mCXCL1 or vCXCL-
1CCMV expression cassette containing a gpt selectable marker was inserted into 
the IE2 region eliminating the puromycin-GFP to generate RMmCXCL1 and 
RMvCXCL1CCMV, respectively. 
 
ie 2          ie 1
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(gfp +) (mck -)














myeloid related protein-8 promoter (Sparer et al., 2004). All mice were housed 
under specific pathogen free conditions.   
Plasmid Constructs  
An EcoRI/PstI digested fragment containing the coding region for vCXCL-
1CCMV or mCXCL1 (KC) was cloned into the EcoRI/PstI digested plasmid 
pcDNA3.1/Zeo immediately downstream of the human cytomegalovirus 
immediate early promoter (HCMV IE). The 1.2kb HCMV IE-chemokine fragment 
was PCR amplified to add flanking restriction sites (underlined) and a C-terminal 
6-His tag using the primers: MluI HCMV IE (5’-
CGACGCGTCGATGTACGGGCCAGATATACGCCTTGACATTGATTAT-3’) and 
SalI 6 His (5’ACGCGTCGACTGGTGGTGGTGGTGGTGACCTCCTCC-3’). The 
PCR fragment was cloned into the pCRII TA vector (Invitrogen) for sequence 
verification. The HCMV IE-chemokine cassette was digested with MluI and SalI 
and cloned into the plasmid L120.1 as illustrated in Figure 12. L120.1 has 5’ and 
3’ sequences from MCMV IE2 for homologous recombination and a gpt 
expression cassette used for selection of recombinant viruses (C. Meiering, 
unpublished data). 
Generation of Recombinant Virus 
 NIH3T3 cells (60% confluent) were transfected with Drd-linearized 
L120.1+vCXCL1-1CCMV or  L120.1+mCXCL1 using Lipofectamine 2000 
(Invitrogen). Three hours post-transfection, the cells were infected with MCMV 





























Figure 12. L120.1 plasmid used for generating RMvCXCL1CCMV and 
RMmCXCL1. This plasmid contains the HCMV IE promoter driving the 
expression of vCXCL-1CCMV or mCXCL1, a gpt marker under the control of the 
HSV TK promoter for selection of recombinant viruses and MCMV ie2 
homologous regions (5’MCMV and 3’MCMV) for recombination into RM4511. 














L120.1+(HCMV IE-vCXCL-1CCMVL120.1+(HCMV IE-vCXCL-1CCMV /mCXCL1)
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selection using growth media supplemented with mycophenolic acid (12.5 g/ml) 
and xanthine (100 g/ml) (Vieira et al., 1994). Recombinant virus was identified 
by the loss of gfp fluorescence and subjected to three rounds of plaque 
purification using an overlay of 0.5% agar in growth media. Virus stocks were 
generated by infecting NIH3T3 cells in T150 flasks at an MOI=0.01. Viral DNA 
was isolated by phenol-chloroform extraction and used for diagnostic PCR to 
verify proper insertion of the chemokine cassette and loss of the puromycin-gfp 
insert. The primers used were: RM4511 F (5’-
CATTGACGTCAATGGTGGGAAAGTACATGGCG-3’), RM4511 gfp R (5’-
CCCGACGCGCGTGAGGAAGAGTTCTTGCAG-3’), and HCMV ie R (5’-
GAACTCCATATATGGGCTATGAACTAATGACC). 
In Vitro Growth Assay 
 M210B4 cells (4x105cells/well) were plated in triplicate in a 6-well dish 
and infected with RM4511, RMvCXCL-1CCMV, or RMmCXCL1 for either a multi-
step (MOI=0.5) or single-step (MOI=5) growth analysis. Supernatants were 
collected at stated times post infection, centrifuged (400x g) to remove 
contaminating cells and sonicated prior to titering. Virus titers were determined 
by standard plaque assay on M210B4s (Lutarewych et al., 1997). 
In Vitro Protein Expression 
 Aliquots from the single-step growth assay were removed and used to 
verify chemokine expression. vCXCL-1CCMV and mCXCL1 were isolated from 100 
g of total protein by incubation with Ni-NTA agarose beads. The eluted protein 
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samples were subjected to Western blot analysis using the primary anti-6-His 
antibody (Qiagen) diluted 1:200 and secondary anti-mouse HRP antibody diluted 
1:2000 . 
In Vivo Growth of Parental and Recombinant Viruses 
 106 PFUs of parental or recombinant viruses were inoculated in the 
footpad of hCXCR2 transgenic mice. At different times post infection, mice were 
sacrificed and their footpads, spleens, liver, lungs, popliteal lymph node, and 
salivary glands were removed. Organs were individually weighed, sonicated in 
growth medium, and centrifuged at 400 X g to pellet debris. Supernatants were 
stored at -80C until titered (Fleming et al., 1999). 
Depletion of Cellular Subsets 
 In vivo depletion of cellular subsets was performed by intraperitoneal (i.p.) 
inoculation of depleting antibody one day prior to MCMV infection and then every 
three days until harvest. Neutrophils were depleted using 1A8 (anti-Ly6C) 
antibody (1mg/ inoculation) (BioXcell, West Lebanon, NH) (Daley et al., 2008). 





Generation of Recombinant Viruses.  
The strict species specificity of the CMVs precludes the use of CCMV in 
the mouse model. Therefore, a recombinant MCMV expressing vCXCL-1CCMV 
was generated to study the role of this protein in virus dissemination. A 
recombinant virus expressing the murine CXC chemokine, mCXCL1 (KC), was 
generated as a control to evaluate specific effects on dissemination due to the 
virally encoded chemokine. mCXCL1 was chosen as it is murine equivalent of 
IL8, which is the closest homologue to vCXCL-1.  MCMV RM4511 was used as 
the parental strain for construction of these viruses because it lacks expression 
of a functional MCMV viral chemokine, MCK2.  This will allow for the in vivo 
analysis of vCXCL-1CCMV and mCXCL1 in the absence of any contribution by the 
MCMV encoded chemokine. 
The recombinant plasmid, L120.1, was constructed to contain either the 
vCXCL-1CCMV or mCXCL1 coding sequence under the control of the HCMV IE 
promoter (Figure 12). This promoter has been used to drive expression of other 
genes inserted in the MCMV genome (Manning et al., 1992) and was chosen to 
ensure adequate chemokine expression. Insertion of the chemokine cassette into 
the ie2 region displaced the puromycin-GFP segment present in RM4511 (Figure 
11). Loss of GFP expression allowed visual selection of recombinant viruses.  
The ie2 gene was previously shown to be dispensable for MCMV replication in 
vitro and in mice (Manning and Mocarski, 1988).  
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Following transfection of NIH3T3 cells with Drd-linearized L120.1+vCXCL-
1CCMV or mCXCL1 and subsequent infection with RM4511; recombinant viruses 
were passaged twice in medium containing mycophenolic acid and xanthine to 
select for recombinant virus expressing gpt. Recombinant virus was identified by 
the loss of GFP expression and plaque purified three times. 
PCR was used to discriminate between RM4511 and the recombinants 
(Figure 13). Chemokine specific primers (forward) and a universal 6 His primer 
(reverse) were used to confirm the presence of the chemokine insert.  No product 
was detected when the parental virus was used as a template (Fig. 13A).  Two 
different primer sets were designed to verify correct insertion of the promoter-
chemokine cassette and loss of the puromycin-gfp segment. The forward primer 
was located upstream of the recombination site in the MCMV genome and was 
used in both diagnostic PCRs.  The reverse primer was specific for the displaced 
(GFP/puromycin)(Figure 13B) or the inserted sequences (HCMV IE promoter) 
(Figure 13C).  Each PCR generated the expected size fragment and confirms 
that the recombination occurred in the correct location with the correct 
orientation. 
In Vitro Growth Kinetics and Chemokine Expression of RMvCXCL-1CCMV 
and RMmCXCL1.  
The growth kinetics of RMvCXCL-1CCMV and RMmCXCL1 were evaluated to 
determine whether insertion of the vCXCL-1CCMV or mCXCL1 cassette affected 
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Figure 13. PCR verification of RMmCXCL1 and  RMvCXCL1CCMV. Three PCR 
reactions were performed using viral DNA as template. A) Amplification of either 
the mCXCL1 or vCXCL-1CCMV gene using HCMV IE and 6 His primers. This 
generates a ~325 bp product (mCXCL1) and a ~425bp (vCXCL-1CCMV). B) 
Verification of the loss of the puromycin-GFP expression cassette using a primer 
flanking the 5’ MCMV IE2 homologous region and a primer within the puromycin-
GFP cassette (MCMV GFP). This generates a 2.3kb product.  C) Verification of 
the correct insertion site of the mCXCL1 or vCXCL-1CCMV expression cassette 
using a primer flanking the 5’ MCMV IE2 homologous region and a primer within 


















































































































































































































































































































































































growth of the recombinant viruses in cell culture. We performed both single 
(MOI=5) and multi (MOI=0.05) step growth curves to identify any growth defects 
in replication or spread of the recombinant viruses relative to the parental strain, 
RM4511. RMvCXCL-1CCMV and RMmCXCL1 replicated as well as RM4511 in 
both assays (Figure 14), indicating the absence of any deleterious mutations 
affecting growth in cell culture. 
 Before evaluating the role of RMvCXCL-1CCMV and RMmCXCL1 in vivo, 
temporal expression of the chemokines in the supernatants of virally infected cell 
was confirmed (Figure 15). Immunoblotting of Ni-NTA-concentrated supernatants 
from each time point of the single step growth curve detected RMvCXCL-1CCMV 
and RMmCXCL1.   Beginning on the second day post infection and continuing for 
the duration of the experiment, both chemokines were detected in the 
supernatants.   This illustrates both host and viral chemokines are secreted in 
detectable quantities by day 2 post infection. 
Dissemination of RMvCXCL-1CCMV and RMmCXCL1 in vivo. 
To evaluate the role of vCXCL-1CCMV in the dissemination of CMV in vivo, 
hCXCR2 transgenic mice were inoculated with RMvCXCL-1CCMV, RMmCXCL1, 
or RM4511 via the footpad to mimic natural MCMV infection. hCXCR2 transgenic 
mice were used because vCXCL-1CCMV does not activate murine CXCR2 (data 
not shown). Because these transgenic mice still express mCXCR2 they retain the 
ability to respond to mCXCL1. This allowed the evaluation of both RMvCXCL-





Figure 14. Recombinant viruses have equivalent growth rates in vitro. NIH3T3 
cells were infected in triplicate with RM4511 or RMvCXCL1CCMV at a MOI of 5 
(single-step) or 0.05 (multi-step). Supernatants were harvested daily for five days 



























































































Figure 15. Recombinant viruses express either mCXCL1 and vCXCL1CCMV in 
vitro. Western blot analysis was used to analyze the expression of mCXCL1 and 
vCXCL1CCMV. NIH3T3 cells were infected with RM4511, RMmCXCL1, or 
RMvCXCL1CCMV at a MOI of 5. Supernatants were harvested at the indicated 
times post infection. Recombinant proteins were isolated using Ni-NTA agarose 
beads from 100 mg of total protein. The eluted protein samples were subjected to 











































































































Following inoculation, virus titers were measured in several organs to 
determine the impact of vCXCL-1CCMV and mCXCL1 on virus dissemination 
(Figure 16). Footpad titers showed no differences, thus the viral chemokines did 
not affect replication or clearance at the site of inoculation. Primary dissemination 
beginning at day 2 is measured by titers in the lymph node, lung and spleen.  
Once again, there were no difference between the recombinants and the parental 
virus (RM4511).  Surprisingly, no virus was recovered in the salivary glands at all 
time points examined in mice infected with the recombinant viruses. RM4511 
was present in the salivary gland but at a lower titer than the MCK2 expressing 
virus, RM4503, as previously shown (Saederup et al., 2001). To ensure that 
dissemination of the recombinant virus to the salivary gland was not delayed, 
salivary glands were titered at 21 dpi.  No virus was detected at this time point 
(data not shown). The absence of the recombinant viruses in the salivary gland 
could represent a defect in dissemination to this site, a lack of replication in the 
salivary gland, or enhanced clearance of these viruses from the salivary gland. 
The absence of RMvCXCL-1CCMV and RMmCXCL1 in the salivary gland is 
not due to adaptive immune response clearance. 
T cells play an important role in controlling CMV infection. CD8+ T cells 
effectively clear MCMV from many organs (Reddehase et al., 1987). However, 
viral clearance from the salivary gland is dependent on CD4+ T cells (Heise, 
Connick, and Virgin, 1998; Lu et al., 2006). To determine the role of the adaptive 
immune response in clearing RMvCXCL-1CCMV and RMmCXCL1 from the 
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Figure 16. Overexpression of host or viral chemokine only affects MCMV 
dissemination to the salivary glands. hCXCR2 mice were inoculated with 106 
PFUs of either RMmCXCL1 (Ñ), RMvCXCL1CCMV (D), RM4511 ( ), or RM4503 
(à ). Salivary glands were harvested 14 dpi and virus titers were determined by 
plaque assay. Horizontal bars represent the mean virus titer (+/- standard 
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salivary gland, SCID mice were infected with recombinant or parental MCMVs.   
Salivary glands were harvested at 14 dpi and titered. Even without an adaptive 
immune response, no virus was recovered from salivary glands from mice 
infected with recombinant viruses (Figure 17).  RM4511 still disseminated to the 
salivary glands. These data indicate that the absence of RMvCXCL-1CCMV and 
RMmCXCL1 in the salivary gland was not due to an amplification of adaptive 
immune response clearance. 
Neutrophils are not responsible for the lack of recombinant viruses in the 
salivary glands. 
Both vCXCL-1CCMV and mCXCL1 bind and activate neutrophils via CXCR2 
(Kobayashi, 2006; Miller-Kittrell et al., 2007). Overexpression of these 
chemokines in the salivary gland may recruit and activate neutrophils triggering 
an inflammatory response capable of clearing the recombinant viruses as they 
disseminate there. To test this possibility, mice were depleted of neutrophils 
using the neutrophil specific antibody 1A8 (anti-Ly6C) before infection with 
RM4511, RMvCXCL-1CCMV, or RMmCXCL1.  At 14 dpi salivary glands were 
titered (Figure 18).  Even after depletion of neutrophils, no virus was recovered 
from the salivary glands from mice infected with RMvCXCL-1CCMV or 
RMmCXCL1.  Interestingly, there was a log decrease in virus titers in the 
RM4511 infected mice. These results show that neutrophils are not responsible 








Figure 17. The adaptive immune response is not responsible for enhanced 
clearance of RMvCXCL1CCMV and RMmCXCL1 in the salivary gland. SCID mice 
were inoculated with 104 PFUs of RMmCXCL1, RMvCXCL1CCMV, or RM4511. 
Salivary glands were harvested 14 dpi and virus titers were determined by 
plaque assay. Horizontal bars represent the mean virus titer (+/- standard 



























Figure 18. Neutrophils are not responsible for absence of RMmCXCL1 and 
RMvCXCL1CCMV in the salivary gland. Mice were depleted of neutrophils using 
anti-Ly6C antibody prior to inoculation with RMmCXCL1, RMvCXCL1CCMV, or 
RM4511. Salivary glands were harvested 14 dpi and titered. Horizontal bars 
represent the mean virus titer (+/- standard deviation) Results are from 5 mice 
and are representative of 2 experiments. No virus was detected in any mice 
infected with RMmCXCL1 or RMvCXCL1CCMV. 
 









MCMVs and that neutrophils have a minor role in the dissemination to the 
salivary gland in MCMV infected mice.   
 
Discussion 
The CCMV chemokine homolog, vCXCL-1CCMV, was previously identified 
as a functional chemokine, activating and recruiting human neutrophils similar to 
the HCMV chemokine, vCXCL-1Tol. The in vivo function of, vCXCL-1CCMV is not 
known and no CCMV model is presently available to study the contribution of this 
protein to CCMV pathogenesis in its natural host. MCMV has been extensively 
studied and current views of HCMV dissemination have come in part from 
research in this model system (Edward S. Mocarski, 2007). MCMV has similar 
tropism to HCMV. Specifically, both viruses undergo a cell-associated viremia 
and virus can be recovered from myelomonocytic cells such as neutrophils, 
monocytes, and their precursors (Bale and O'Neil, 1989; Saltzman, Quirk, and 
Jordan, 1988). The mechanism and relative contribution of each cell type to viral 
dissemination has not been sufficiently defined. Dissemination of MCMV to the 
salivary gland is enhanced by the virally encoded  chemokine, MCK2, while 
spread to other organs occurs in a MCK2-independent manner (Saederup et al., 
2001). We reasoned that using RM4511, a mutated MCMV strain lacking MCK2, 
to generate a MCMV expressing vCXCL-1CCMV would allow us to evaluate the 
impact of vCXCL-1CCMV on virus dissemination. To determine if effects of vCXCL-
1CCMV on dissemination were unique to the viral chemokine or whether virally 
 91
encoded host chemokines would produce comparable outcomes, we created 
RMmCXCL1, a MCMV expressing mCXCL1, a homolog of hCXCL8 (IL8). 
vCXCL-1CCMV and hCXCL8 were functionally similar when assessed in vitro 
(Miller-Kittrell et al., 2007). 
The dissemination pattern of RMvCXCL-1CCMV and RMmCXCL1 was 
similar to RM4511 except in the salivary gland (Figure 16). Seeding of organs 
such as the spleen, lymph node, and lung occurs following an initial low-level 
viremia that is not affected by expression of MCK2 (Saederup et al., 2001). 
Therefore, it was hypothesized that dissemination of the recombinant viruses to 
these sites would follow a pattern similar to RM4511 independent of their 
chemokine expression. Our data show that replication and clearance at the site 
of inoculation is equivalent between the recombinants and the parental virus.  
Likewise, primary dissemination is unaffected by expression of vCXCL-1CCMV or 
mCXCL1.  In contrast, both RMvCXCL-1CCMV and RMmCXCL1 were absent from 
the salivary gland as late as 3 weeks post infection.  
There are three possible explanations for the lack of recombinants in the 
salivary glands.  First, these viruses are unable to replicate in the salivary glands.  
Other recombinants have shown a salivary gland growth defect (Manning et al., 
1992). We excluded this possibility because neither independently generated 
recombinant was recovered from the salivary gland. The chance event of 
affecting the salivary gland growth gene (sgg) in two separately isolated 
recombinants makes this highly unlikely. We have also found that when mice are 
treated with the anti mitotic drug, cyclophosphamide, which depresses the 
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immune response, both recombinants can be titered in the salivary gland 
(appendix 2).  This demonstrates that both viruses can replicate in the salivary 
gland and that the defect is in dissemination.   
Second, overexpression of the chemokine could lead to an overactive 
immune response resulting in increased clearance from the salivary gland.  Our 
data shows that in the primary organs, there are no differences in viral clearance 
(Figure 16).  If there was increased clearance from the salivary gland, elimination 
of the adaptive immune response (Figure 17) and depletion of neutrophils (Figure 
18) should have lead to recovery of the recombinant viruses from the salivary 
glands. This minimizes this possibility. 
Third, the chemokines could lead to a salivary gland dissemination defect.  
When initially designing these recombinants, we expected that overexpression of 
host or viral chemokines would lead to increased dissemination to the salivary 
gland. To the contrary, overexpression of host or viral chemokine leads to no 
dissemination to the salivary glands.  Since depletion of neutrophils did not 
restore dissemination to the salary gland, another cell type that expresses 
CXCR2 and is not depleted with the anti-Ly6C antibody would likely be 
responsible. Our data cannot eliminate the possibility that this other cell type is 
involved in clearance from the salivary gland or that normal dissemination to the 
salivary gland is masked when this cell type is recruited and activated in the 
primary organs. Our data implicate a cell of the myeloid lineage unless these 
chemokines have an undefined interaction with a chemokine receptor present on 
some other cell type. Although an exhaustive analysis of vCXCL-1CCMV receptor 
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usage has not been completed, mCXCL1 receptor usage is well characterized 
(Lee et al., 1995) and both have the same phenotype in our experiments.  
Experiments are currently in progress using a mCXCR2-blocking antibody to 
determine the role of CXCR2 in the clearance of RMmCXCL1. This antibody is 
not appropriate for evaluating RMvCXCL-1CCMV since it will not block hCXCR2 
but the two recombinants are likely cleared by a common mechanism and this 
may be elucidated by study of RMmCXCL1 dissemination in the absence of 
CXCR2. 
Our data suggests that the inability to recover RMvCXCL-1CCMV and 
RMmCXCL1 from the salivary gland, even in the absence of an adaptive immune 
response or following neutrophil depletion, may be due to defective 
dissemination of these recombinant viruses. MCMV encodes a number of gene 
products that contribute to viral replication and dissemination to the salivary 
gland. The sgg1 gene is important for MCMV replication in the salivary gland 
although the mechanism for this is not known (Lagenaur et al., 1994). The 
MCMV G protein-coupled receptor homolog, M33, is also needed for efficient 
salivary gland replication based on mutagenesis studies (Case et al., 2008; 
Davis-Poynter et al., 1997; Sherrill and Miller, 2006). Dissemination of MCMV to 
the salivary gland is enhanced by the virally encoded chemokine, MCK2, while 
spread to other organs occurs in a MCK2-independent manner. That MCMV has 
so many genes regulating the spread and replication of the virus to the salivary 
gland highlights the importance of this organ to MCMV biology, as it is both a site 
of viral persistence and of transfer of virus from host to host (Ho, 1991; Shellam, 
 94
2007). It also suggests MCMV may require unique mechanisms to facilitate 
dissemination to and growth in the salivary gland as these genes have little to no 
impact on the recovery of MCMV in other organs. However, the reasons for this 
are unclear. Perhaps the cells of the salivary gland don’t adequately support viral 
replication or the virus has difficulty gaining access to this site. The latter is 
supported by the observation that MCK-2 dependent dissemination to the 
salivary gland is associated with increased recruitment of myelomonocytic cells 
to the inoculation site (Noda et al., 2006) suggesting viral spread to the salivary 
gland is otherwise inefficient. Our continued work with RMvCXCL-1CCMV and 
RMmCXCL1 may help better elucidate the mechanism of MCMV dissemination 






























































The hypothesis of this study was that vCXCL-1CCMV is a functional CXC 
chemokine that contributes to viral dissemination. To address this, we initially 
compared the in vitro functional and biochemical characteristics of vCXCL-1 from 
Toledo HCMV and CCMV in neutrophils. Neutrophils may be associated with the 
pathobiology of HCMV infection. Neutrophilic infiltrates are found in AIDS 
patients who have CMV related retinitis (Holland et al., 1983; Pepose et al., 
1985). Furthermore, HCMV is frequently isolated from neutrophils of 
immunocompromised patients (Martin et al., 1984; Saltzman, Quirk, and Jordan, 
1988; van der Bij et al., 1988a) and these cells are able to transmit infectious 
virus (Saltzman, Quirk, and Jordan, 1988). Thus neutrophils may have a role in 
disseminating HCMV.  
The two primary CXC receptors on neutrophils are CXCR2 and CXCR1. 
Since vCXCL-1Tol binds exclusively to CXCR2 (Penfold et al., 1999), we 
measured binding of vCXCL-1CCMV to this receptor. vCXCL-1CCMV had a lower 
affinity for human CXCR2 compared to vCXCL-1Tol and the host chemokine, 
hCXCL1. This difference could reflect a difference in affinity of vCXCL-1CCMV for 
human CXCR2 versus chimpanzee CXCR2. While known CXCR2 receptor 
binding motifs are conserved in these two species, analyzing the binding of 
vCXCL-1CCMV to CXCR2 on chimpanzee neutrophils would help address this 
possibility. It is more likely that differences in the viral chemokines themselves 
are responsible for the differences in binding affinity. This may be due in part to 
the mutated ELR motif (LM) present in vCXCL-1CCMV or the variability within 
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the N-loop region since both are important in receptor binding and signaling 
(Clark-Lewis et al., 1991; Schraufstatter et al., 1993).  
We measured calcium mobilization to evaluate vCXCL-1CCMV’s ability to 
activate neutrophils. Remarkably, vCXCL-1Tol and vCXCL-1CCMV were found to 
have similar activation potentials despite the mutation in the ELR sequence of 
vCXCL-1CCMV. Mutations in this residue impair neutrophil activation by cellular 
chemokines (Clark-Lewis et al., 1993). Nevertheless, vCXCL-1CCMV could not 
completely desensitize neutrophils to hCXCL1. The lower binding affinity of 
vCXCL-1CCMV likely contributes to this, since receptor desensitization is 
determined in part by the binding affinity of the chemokine.  In converse, hCXCL1 
showed complete desensitization to vCXCL-1CCMV. hCXCL1 binds exclusively to 
CXCR2, suggesting vCXCL-1CCMV activates only CXCR2 on neutrophils, 
although we have not evaluated the ability of vCXCL-1CCMV to antagonize other 
receptors.  
We also examined activation of the ERK and Akt pathways by vCXCL-
1CCMV and vCXCL-1Tol. These pathways are important in chemokine-mediated 
signaling that affect cell survival, expression of adhesion molecules, and 
chemotaxis (Murphy, 2003). Interestingly, the activation of ERK and Akt signaling 
was similar among the host and viral chemokines.  This was surprising given that 
vCXCL-1CCMV bound CXCR2 less efficiently than the other chemokines tested 
and indicates that the crucial interactions between vCXCL-1CCMV and CXCR2 
needed to induce these pathways are maintained.  
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We analyzed vCXCL-1CCMV and vCXCL-1Tol in several functional assays to 
identify mechanisms that might relate to the interaction of CMV with neutrophils 
in vivo. vCXCL-1CCMV induces migration of neutrophils as does vCXCL-1Tol 
(Penfold et al., 1999). This could enable CMV to modulate the immune response; 
directly or indirectly recruiting cells that support viral replication or that facilitate 
dissemination. Dissemination of MCMV to the salivary gland depends on 
recruitment of myeloid progenitor cells by the viral chemokine, MCK2 (Noda et 
al., 2006) and could be important to the pathogenesis of other CMVs. 
vCXCL-1CCMV and vCXCL-1Tol were also found to suppress apoptosis in 
neutrophils and upregulate members of the 2-integrin adhesion family, both of 
which may contribute to viral dissemination. Inhibition of neutrophil apoptosis by 
vCXCL-1CCMV and vCXCL-1Tol could aid virus dissemination by prolonging the 
lifespan of CMV infected cells. The CMVs encode a number of proteins that 
interfere with apoptosis (Andoniou and Degli-Esposti, 2006) and our data shows 
the viral chemokines vCXCL-1CCMV and vCXCL-1Tol also interfere with this 
process. Secretion of these chemokines could inhibit apoptosis in nonpermissive 
cells such as neutrophils or monocytes that would not express the virally 
produced anti-apoptotic proteins. 2-integrins are important in the adhesion and 
extravasation of circulating neutrophils across the endothelium. HCMV infected 
endothelial cells have been shown to transmit virus to neutrophils (Grundy et al., 
1998). Therefore, upregulation of 2-integrins might enhance the transmission of 
CMV to neutrophils as well as facilitate the spread of infected cells to the tissues.  
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Our in vitro findings provide circumstantial evidence for a role of vCXCL-1 
in the activation and recruitment of neutrophils for CMV dissemination. We 
initially evaluated vCXCL-1CCMV function in vivo using the MCMV mouse model. 
Since the species specificity of the CMVs precludes the use of CCMV in the 
mouse model, we generated recombinant MCMVs expressing either vCXCL-
1CCMV or the control host chemokine, mCXCL1.  
In vivo, RMvCXCL1CCMV and RMmCXCL1 showed similar primary 
dissemination to the lymph node, lung and spleen as the parental virus RM4511. 
Recombinant virus was not recovered in the salivary glands at any time point 
examined despite the detection of RM4511 within 7dpi. This was unexpected as 
we anticipated that overexpression of host or viral chemokines would increase 
dissemination to the salivary gland as seen with the MCMV chemokine, MCK2.  
Since T cells play a large role in clearing MCMV, we evaluated 
dissemination of RMvCXCL-1CCMV and RMmCXCL1 to the salivary gland in the 
absence of the adaptive immune response. However, no virus was recovered 
from the salivary glands of SCID mice infected with recombinant virus. Innate 
immune cells, particularly natural killer cells, also help clear MCMV from various 
organs (Shellam, 2007). However, it’s unlikely NK cells mediated clearance of 
the recombinants from the salivary gland since NK cell induction would enhance 
clearance of the recombinants in other organs as well. Since both vCXCL-1CCMV 
and mCXCL1 activate neutrophils via CXCR2 (Kobayashi, 2006; Miller-Kittrell et 
al., 2007), we considered that the recombinant virus defect was neutrophil-
dependent. Interestingly, we found RM4511 salivary gland titers were reduced in 
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neutrophil-depleted mice. This shows neutrophils have a role in the 
dissemination of MCMV to the salivary gland. However, no recombinant virus 
was recovered from the salivary glands of neutrophil-depleted mice. Therefore, 
neutrophils are not responsible for the absence of RMvCXCL-1CCMV and 
RMmCXCL1 in the salivary gland.   
These findings suggest RMvCXCL-1CCMV and RMmCXCL1 may 
disseminate poorly to the salivary gland. Overexpression of vCXCL-1CCMV and 
mCXCL1 may recruit a cell type that interferes with the normal dissemination of 
MCMV. To begin to address this possibility we could examine the cellular 
infiltrate at the site of virus inoculation to identify different cell types recruited by 
RMvCXCL-1CCMV and RMmCXCL1 compared to the parental MCMV. 
Alternatively, recombinant virus chemokine expression could alter cellular 
trafficking such that virus is delivered to a salivary gland cell type that is not 
permissive for replication. 
In conclusion, this study is the first to characterize the CCMV viral 
chemokine, vCXCL-1, and show it is functionally similar to vCXCL-1Tol. 
Therefore, the study of vCXCL-1CCMV may contribute to a better understanding of 
its HCMV homolog. Furthermore, this research is the first to evaluate the role of a 
CMV CXC chemokine in vivo. Future work evaluating the role of other viral and 
host chemokines in vivo using the mouse model will likely advance our 
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Prokaryotic Expression of pUL146a 
Introduction 
The use of baculoviruses is well established for the expression of 
recombinant proteins. This system allows for the post-translational modification 
of many eukaryotic proteins including glycosylation, proper folding, and secretion 
of proteins with signal sequences (Vialard, Arif, and Richardson, 1995). 
Specifically, this system has been used to produce a number of different 
chemokines and was the method used in generating the protein in this study, 
vCXCL-1CCMV (Imai, 2000). However, attempts to express the related protein, 
CCMV pUL146a, using the baculovirus system were unsuccessful. Although 
recombinant baculovirus was generated as determined by infectious centers 
assay, evidence of pUL146a secretion from insect cells was never detected by 
silver stain or western blot analysis. It was considered that improper processing 
of the signal sequence could lead to sequestration of the protein in the cell but 
this possibility was eliminated when pUL146a was not detected in cell lysates. 
Therefore, a prokaryotic expression system was chosen for the expression of 
pUL146a.  
While bacterial expression is fast and can produce high protein yields, 
there are a number of shortcomings in expressing eukaryotic proteins. Proteins 
produced by this method are not glycosylated, are not secreted, and can lack 
disulfide bonds that would help in correct folding. Additionally, the production of 
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large quantities of recombinant protein can result in the accumulation of 
improperly folded protein in inclusion bodies within the cell (van Kimmenade et 
al., 1988). Although pUL146a has no predicted glycosylations (data not shown), 
the function of chemokines depends on a correctly folded protein, which is due in 
part to the formation of disulfide bonds (Fernandez and Lolis, 2002). 
Nevertheless, many bacterial expression systems have been engineered to allow 
many of these modifications, including protein secretion, and formation of 
disulfide bonds, among others. In fact, many commercially available chemokines 
are manufactured using these systems. Therefore, in light of the failures in 
expressing pUL146a in the baculovirus system, an E. coli based system was 
tested for the expression of this protein. 
 
Materials and Methods 
Plasmids and Bacterial Strains  
The E. coli strain AD494 (Novagen) was used for protein expression. This 
bacterial strain allows disulfide bond formation due to a mutation in the 
thioredoxin reductase gene that is maintained under kanamycin selection.  The 
UL146a gene was cloned into the pET-22b expression plasmid (Novagen). 
Expression in pET-22b from the T7lac promoter is inducible allowing control of 
the expression conditions. The ampicillin and kanamycin needed for selection 
were used at a final concentration of 50 g/ml and 15 g/ml, respectively. 
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Cloning of UL146a into E. coli strain AD494  
Since cleavage of the signal sequence would not occur in AD494, primers 
were designed to clone UL146a beginning at the first amino acid following the 
predicted signal sequence cleavage site. The primers used were: pET24a+146a 
F (NdeI)-5’gcgcgcgCATATGgtcacaagagaacaacactgt-3’ and CCMV UL146a 6His 
(BamHI)-5’-cgGGATTCgttagtggtggtggtggtggtgtcctcccaggatagctac-3’. Cloning into 
the NdeI site of pET22-b provides the initiating methionine needed for protein 
expression. The PCR product was initially cloned into the pcrII vector (Invitrogen) 
and sequenced to confirm the absence of mutations in the gene sequence. The 
UL146a gene was subsequently cloned into the pET-22b plasmid following 
restriction digest of both the UL46a fragment and pET-22b with NdeI and BamHI. 
AD494 cells were made competent according to the protocol shown in Figure 19. 
Finally, pET-22b+UL146a was transformed into AD494 cells using the standard 
procedure for transformation of E. coli JM109 cells (Promega Technical Bulletin 
TB095). Following verification by restriction digest, glycerol stocks of 
transformants containing pET-22b+UL146a were stored at -80C for later use. 
Induction of UL146a Expression  
One day prior to induction a 15 ml culture of AD494-(pET-22b+UL146a) 
was grown in LB broth with ampicillin and kanamycin to an OD600=0.7 and stored 
at 4C, overnight. The following day, the starter culture was centrifuged to 




Preparation of Competent Cells 
 
1. Inoculate 10 ml LB broth with a bacterial colony; grow overnight at 37ºC. 
2. Transfer 1-2 ml to 100 ml prewarmed LB broth and allow to grow at 37ºC 
with shaking to OD600=0.5 (approximately 2-3 hours). 
3. Divide culture into two tubes and centrifuge at 3000 rpm for 15 min at 4ºC. 
4. Pour off supernatant and gently resuspend each pellet in 33 ml of Buffer 
RF1.   
5. Incubate tubes on ice for 20 min. 
6. Centrifuge cells at 3000 rpm for 15 min at 4ºC. 
7. Pour off supernatant and carefully add 5 ml of Buffer RF2 to each tube. 
8. Resuspend pellet by gently swirling or rocking tube. Pellet will be loosely 
distributed along entire side of centrifuge tube.   
9. Incubate cells on ice for 15 min. 
10. Place Eppendorf tubes on dry ice and distribute aliquots into tubes. 
11. Place cells at –80ºC. 
 
Buffer RF1 
Compound Final Concentration Amount/liter Amount/200 ml
RbCl 100 mM 12.0 g 2.4 g 
Mn2Cl-4 H2O 50 mM 9.9 g 1.98 g 
Potassium Acetate 
(1 M stock, pH 7.5) 
30 mM 30 ml 6.0 ml 
CaCl2-2 H2O 10 mM 1.5 g 0.3 g 
Glycerol 15% 150 ml 30 ml 
Adjust pH to 5.8 with acetic acid (~1 drop).  Filter sterilize. 
 
Buffer RF2 
Compound Final Concentration Amount/liter Amount/50 ml
MOPS 
(0.5 M stock, pH 6.8) 
10 mM 20 ml 1 ml 
RbCl 10 mM 1.2 g 0.06 g 
CaCl2-2 H2O 75 mM 11 g 0.55 g 
Glycerol 15% 150 ml 7.5 ml 
Adjust pH to 6.8 with 1 N NaOH (~1 drop).  Filter sterilize. 
 
Figure 19. Protocol for the preparation of competent bacteria. 
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was used to inoculate 250 ml of fresh LB broth with antibiotics and grown at 37C 
until an OD600 of 0.4-0.6. A preinduction sample was collected for later analysis. 
Protein expression was induced by adding IPTG to the culture at a final 
concentration of 1 mM and incubating for an additional 3-4 hours. Alternatively, 
expression was induced with 0.5 mM IPTG at 37C or with 1 mM IPTG at 30C 
as stated. Cells were harvested by centrifugation at 5,000 x g for 15 minutes. A 
postinduction sample was removed for later analysis and the remainder of the 
supernatant was discarded. The cell pellet was stored at -80C until protein 
isolation.   
Protein Purification  
Frozen cell pellets were allowed to thaw on ice for 15 minutes prior to 
purification. Otherwise, cell pellets were resuspended in 5 ml of lysis buffer. For 
lysis under native conditions the lysis buffer contained 50 mM NaH2PO4, 300 mM 
NaCl, and 10 mM imidazole, adjusted to pH 8. Lysis under denaturing conditions 
used lysis buffer containing 100 mM NaH2PO4, 10 mM Tris-Cl, and 8 M urea, 
adjusted to pH 8. The cells were lysed by sonication using six 30-second bursts 
with a 30 second rest between each cycle. Lysates were centrifuged at 10,000 x 
g for 20 minutes. To isolate soluble pUL146a, the supernatant was incubated 
with Ni-NTA agarose beads at a ratio of 50 l of beads for each milliliter of 
supernatant. Alternatively, to isolate insoluble protein from inclusion bodies a 
refolding procedure was performed prior to incubation with the Ni-NTA beads. 
The pellet was resuspended in 5 ml of denaturing buffer containing 5 M 
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guanidine thiocyanate, 50 mM Tris (pH 8), 50 mM NaCl, 1 mM EDTA, and 10 
mM mercaptoethanol and incubated for 1 hour. Forty-five ml of refolding buffer 
(denaturing buffer without guanidine thiocyanate or mercaptoethanol) was slowly 
added to the resuspended pellet using a peristaltic pump at a rate of 250 
l/minute. Refolded protein samples were incubated with Ni-NTA beads as stated 
above. Beads were washed with PBS and eluted using 500 mM imidazole when 
performed under native or refolding conditions. To elute denatured proteins, 
elution buffer of identical composition to the denaturing lysis buffer adjusted to 
pH 4.5 was used. Protein samples were analyzed by either silver stain or western 
blot analysis. 
 
Results and Discussion 
pUL146a was successfully expressed in AD494 cells. As shown in Figure 
20, the protein was not present in pre-induced samples demonstrating the tight 
regulation of this system and the absence of “leaky” expression prior to addition 
of IPTG. Additionally, pUL146a was present in cells but not in the media 
consistent with the inability of this protein to be secreted from bacterial cells. 
However, attempts to purify pUL146a from cellular lysates under native 
conditions failed. Therefore, it was considered that the protein detected in the cell 
pellet might be contained within inclusion bodies. This was supported by the 
detection of pUL146a in the insoluble fraction but not the supernatants following 
















Figure 20. Expression of pUL146a in E. coli. Samples were collected pre- and 
post-induction with IPTG. pUL146a was purified by incubation with Ni-NTA 































structurally important to chemokines and improper formation of these bonds 
could result in an incorrectly folded protein. Although, E. coli AD494 has 
amutation to prevent reduction of disulfide bonds other enzymes are present that 
may have reducing potential (Prinz et al., 1997). Second, the high protein yield of 
bacterial systems can also result in large amounts of unfolded or misfolded 
proteins (Lilie, Schwarz, and Rudolph, 1998).  Modifications to the induction 
protocol to decrease protein expression by slowing growth or decreasing the 
amount of IPTG can sometimes improve recovery of protein from the soluble 
fraction. Therefore, induction using 0.5 mM IPTG or incubation at 30C instead of 
37C was tested in an attempt to improve the recovery of soluble pUL146a. The 
altered induction conditions appeared to produce slightly lower protein yields 
overall, however the protein was still largely insoluble (Figure 21). Since a 
correctly folded protein was needed a refolding procedure was used in an 
attempt to produce a renatured, functional protein (van Kimmenade et al., 1988). 
Although the refolding procedure was attempted on numerous occasions 
pUL146a was never identified in the refolded fraction (data not shown). The 
refolding procedure consistently resulted in precipitate formation thus the proper 
conditions for renaturation may not have been achieved.  
Despite an inability to generate soluble pUL146a using the parameters 
described, there are several additional modifications that could improve the 
purification of properly folded protein using a bacterial expression system. First, a 
different bacterial strain may be appropriate. Although use of AD494 can improve 





Figure 21. Induction of pUL146a expression. Bacterial cultures were induced 
using the standard method (1mM IPTG, 37°C) or with lowered induction (O.5 mM 
iPTG or 30°C) to evaluate the recovery of soluble protein by each method. 




















































additional reductase genes. Use of these strains can further enhance the 
formation of disulfide bonds resulting in better protein solubility (Bessette et al., 
1999). Alternatively, a cloning protocol that allows periplasmic localization 
enhances folding of many proteins (Barth et al., 2000). A number of plasmids of 
the pET series, including pET-22b, encode signal sequences that target the 
expressed protein for transport to the periplasmic space. Additionally, inducing 
protein expression under conditions of osmotic stress has been a successful 
strategy for the periplasmic production of functional proteins (Blackwell and 
Horgan, 1991). In the future, use of one or more of these strategies may be 














Evaluation of Recombinant MCMVs  
Introduction 
The dissemination pattern of RMvCXCL-1CCMV and RMmCXCL1 was 
similar to RM4511 except in the salivary gland. Primary dissemination of MCMV 
is not affected by expression of MCK2 (Saederup et al., 2001). Therefore, it was 
hypothesized that dissemination of the recombinant viruses to these sites would 
be similar to RM4511 independent of their chemokine expression. Our data show 
replication at the inoculation site and primary dissemination is unaffected by 
expression of vCXCL-1CCMV or mCXCL1.  In contrast, both RMvCXCL-1CCMV and 
RMmCXCL1 were absent from the salivary gland up to 3 weeks post infection. 
To further characterize the salivary gland defect of the recombinant 
MCMVs we depleted different inflammatory cells. Recombinant and parental 
viruses were inoculated in Balb/c mice treated with cyclophosphamide. 
Cyclophosphamide is an established, although not highly specific, method for 
depleting neutrophils. Since both vCXCL-1CCMV and mCXCL1 activate neutrophils 
via CXCR2 (Kobayashi, 2006; Miller-Kittrell et al., 2007), the recombinant virus 
defect may be neutrophil-dependent. As an additional control, we evaluated virus 
growth in Balb/c mice. Our previous studies were in hCXCR2 transgenic mice. 
Without hCXCR2 present, we predicted RMmCXCL1 would maintain the salivary 
gland defect using the endogenous mCXCR2 receptor while RMCXCL-1CCMV 
would resemble RM4511 as the viral chemokine does not function via mCXCR2. 
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Materials and Methods 
Cyclophosphamide Treatment 
In vivo depletion of granulocytes was performed by intraperitoneal 
inoculation of 200L of cyclophosphamide (Sigma) per mouse. High dose 
cyclophosphamide treatments (150mg/kg) were administered on days –5 and –1 
prior to virus inoculation. Low dose cyclophosphamide treatments (100mg/kg) 
were administered beginning on day 3 post-inoculation and continued every 
three days until harvest. Verification of depletion was determined by FACS 
analysis of peripheral blood cells stained with anti-GR-1 and anti-Mac-1 
antibodies (Pharmingen) (Figure 22). 
Recombinant Virus Infection of Balb/c Mice 
106 PFUs of parental or recombinant virus was inoculated in the footpad of 
Balb/c mice. The salivary glands were removed from the mice 14 days post 
infection. Organs were weighed, sonicated in growth medium, and centrifuged at 
400 X g to pellet debris. Supernatants were stored at -80C until titered. 
 
Results and Discussion 
Cyclophosphamide Restores Growth/Dissemination to the Salivary Gland  
RMvCXCL-1CCMV and RMmCXCL1 were both recovered from the salivary 





Figure 22. Depletion of neutrophils in cyclophosphamide treated mice. Peripheral 
blood leukocytes were isolated from each mouse and stained with a 1:200 
dilution of anti-GR-1 and anti-Mac-1 antibodies to verify the depletion of 








































































































































































Figure 23. Cyclophosphamide treated mice show higher titers of RMvCXCL1CCMV 
and RMmCXCL1 in the salivary gland. Mice were treated with cyclophosphamide 
(CY) prior to inoculation with RMmCXCL1, RMvCXCL1CCMV, or RM4511. Salivary 
glands were harvested 14 dpi and titered. Results are from 10 mice and 
represent two experiments. P values were calculated using the student’s t-test 
and are as follows: RM4511 (p= 0.096), RMvCXCL1CCMV (p= 0.112), 
RMmCXCL1 (p= 0.105). 
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Recombinant virus titers were lower than parental virus titers even with 
cyclophosphamide treatment. This may be due to a defect in dissemination of 
these viruses to the salivary gland, inefficient replication in this organ, or 
clearance by cells in addition to neutrophils. This finding is in contrast to 
neutrophil depletion studies. Neither recombinant could be detected in the 
salivary gland of mice treated with 1A8 (Figure 18). This antibody is considered 
more selective in depleting neutrophils (Daley et al., 2008) suggesting the 
cyclophosphamide regimen depletes other cells besides neutrophils that clear 
RMvCXCL-1CCMV and RMmCXCL1 from the salivary gland. Although 
cyclophosphamide is often used to induce neutropenia, it is myelosuppressive 
and some reports have shown cyclophosphamide decreases other cells of this 
lineage (Zuluaga et al., 2006). In this scenario, cyclophosphamide depletes a 
myeloid cell that is CXCR2 positive and responds to both vCXCL-1CCMV and 
mCXCL1, contributing to clearance from the salivary gland. 
Alternatively, cyclophosmamide treatment may facilitate dissemination of 
the recombinant viruses to the salivary gland by recruiting a cell type capable of 
trafficking to this organ. It has been noted that cyclophosphamide treatment 
induces a late myeloid progenitor cell (Angulo et al., 2000; Pelaez et al., 2001). 
This cell type is similar to the MCK2 induced cell type, which contributes to the 
dissemination of the virus to the salivary gland (Noda et al., 2006). Therefore, the 
absence of RMvCXCL-1CCMV and RMmCXCL1 in the salivary gland could result 
from the inability of these viruses to recruit an appropriate cell for dissemination. 
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Cyclophosphamide treatment induces a GR-1Int Mac-1hi population which allows 
some dissemination of virus to the salivary gland.  
Dissemination of RM4511 was not increased following cyclophosphamide 
treatment. This is unexpected if the previous explanation were true. Previously it 
was shown that MCK2 induces late myeloid progenitor cells (GR-1Int Mac-1hi) 
(Noda et al., 2006) thus an increase in this population in cyclophosphamide 
treated mice would be expected to increase dissemination of RM4511 to the 
salivary gland. In contrast, RM4511 salivary gland titers decreased in mice 
treated with cyclophosphamide and the anti-Ly6C antibody. Although not 
significant, this decrease was consistently observed and could indicate that 
neutrophils play a small role in the dissemination of MCMV to the salivary gland. 
These data point to the complexity of MCMV dissemination, inducing some 
inflammatory cells to aid dessemination to the salivary gland while avoiding the 
detrimental effects of an overactive immune response. 
Growth of Recombinant MCMV in Balb/c Mice 
RM4511 titers were similar in the transgenic and Balb/c mice indicating 
dissemination of RM4511 in the two mice strains is similar (Figure 24). However, 
RMvCXCL-1CCMV and RMmCXCL1 were not recovered from the salivary gland of 
Balb/c mice. It is expected that overexpression of vCXCL-1CCMV and mCXCL1 
likely contributed to our inability to recover virus from the salivary gland thus the 
cell  type involved would likely  express CXCR2. mCXCL1 can bind and activate 
















Figure 24. RMmCXCL1 and RMvCXCL1CCMV are not recovered from the salivary 
glands of Balb/c mice. Balb/c mice were inoculated with 106 PFUs of 
RMmCXCL1, RMvCXCL1CCMV, or RM4511. Salivary glands were harvested 14 
dpi and virus titers were determined by plaque assay. Horizontal bars represent 
the mean virus titer (+/- standard deviation). Results are from 5 mice and 













salivary gland defect should be evident in both mouse strains. In contrast, we 
expected to recover RMvCXCL-1CCMV in the salivary gland of Balb/c mice. Since 
vCXCL-1CCMV is unable to activate mCXCR2 based on analysis of calcium 
mobilization, we expected this chemokine to be inactive in Balb/c mice. Our 
finding that RMvCXCL-1CCMV was not recovered from the salivary gland of these 
mice has several possible explanations. RMvCXCL-1CCMV could activate 
mCXCR2 and our calcium mobilization data did not accurately show this. 
Alternatively, RMvCXCL-1CCMV might activate a receptor other than CXCR2 that 
is present in both mouse strains. Finally, the salivary gland defect could be 
unrelated to chemokine expression and due to a currently unidentified difference 





















Cytomegalovirus Immune Modulation  
Introduction 
After an initial primary infection herpesviruses establish latency for the life 
of the host with periodic and spontaneous reactivation.  The coevolution of 
herpesviruses with their host has provided an opportunity for these viruses to 
evolve mechanisms to modulate the host immune response. While some virally 
encoded proteins facilitate immune evasion, interfering with the hosts ability to 
efficiently recognize and clear virus, others induce or alter specific immune 
responses to benefit the viral life cycle. The herpesvirus family members, 
cytomegaloviruses (CMVs), are no exception and encode numerous genes that 
alter both innate and adaptive immune responses (Tables 2 and 3).  
 
Innate Immune Responses 
I. Complement Cascade 
The complement system is composed of a number of plasma proteins that 
induce inflammatory mediators, opsonize pathogens, and can lyse pathogens 
and infected cells. The binding of complement proteins to antibody-antigen 
complexes activates the classical complement pathway: bridging innate and 
humoral immune responses. The alternative pathway is initiated by the binding of  
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Table 2. Cytomegalovirus Modulation of Innate Immune Responses.  






FC Receptor Homolog 
gp34 TRL11/IRL11 HCMV Function unknown 
gp68 UL119-UL118 HCMV Function unknown 
fcr-1 m138 MCMV  NK ligands H60 and MULT-1 
Interferon-Mediated Immunity 
IE1-p72 IE1 HCMV Inhibits ISGF3 
IE86 IE2 HCMV  IFN expression 
pp65 UL83 HCMV  ISGs 
M27 M27 MCMV  STAT-2 
m142/m143 m142/m143 MCMV  PKR activity 
TRS1/IRS1 TRS1/IRS1 HCMV  PKR activity 
Natural Killer Cells 
gpUL18 UL18 HCMV 
MHC I homolog; alters NK cell 
function 
gpUL142 UL142 HCMV MHC I homolog;  NK cell function 
gpUL141 UL141 HCMV  CD155 expression 
gpUL16 UL16 HCMV  NK cell function 
UL40 peptide UL40 HCMV  NK cell function 
m157 m157 MCMV MHC I homolog;  NK cell function 
m144 m144 MCMV MHC I homolog;  NK cell function 
gp40 m152 MCMV  NK ligands of the RAE-1 family 
m145 m145 MCMV  NK ligand MULT-1 
m155 m155 MCMV  NK ligand H60 
Cytokine Homologs 




Table 2. Continued. 
Protein Gene Virus Function 
RhcmvIL-10  RhCMV Induces anti-inflammatory response 
Cytokine Receptor Homologs 
UL144 UL144 MCMV Blocks T cell proliferation 
Viral Chemokine Homologs 
vCXCL-1 UL146 HCMV Activates neutrophils 
vCXCL-1 UL146 CCMV Activates neutrophils 
pUL147 UL147 HCMV Function unknown 
pUL128-131 UL128-131 HCMV Mediate viral entry/cell tropism 
MCK2 m129/131 MCMV   salivary gland dissemination 
pr131 r131 RCMV   salivary gland dissemination 
GPCMV-MIP Unknown GpCMV Activates HCCR-1 
Chemokine Receptor Homologs 
pUS28 US28 HCMV 
Constitutive signaling; binds 
chemokine 
pUS27 US27 HCMV Function unknown 
pUL33 UL33 HCMV Constitutive signaling 
pR33 R33 RCMV Needed for salivary gland replication 
pM33 M33 MCMV Needed for salivary gland replication 
pUL78 UL78 HCMV Function unknown 
pR78 R78 RCMV Function unknown 
pM78 M78 MCMV Function unknown 
Chemokine Binding Proteins 
pUL21.5 UL21.5 HCMV Binds CCL5 
Apoptosis 
vICA UL36 HCMV Inhibits extrinsic apoptosis 
vMIA UL37x1 HCMV Inhibits intrinsic apoptosis 
m38.5 m38.5 MCMV Inhibits apoptosis 
M45 M45 MCMV Inhibits death receptor signaling 
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Table 3. Cytomegalovirus Modulation of Adaptive Immune Responses. 
 
Protein Gene Virus Function 
T Cell Mediated Immunity 
gpUS3 US3 HCMV Inhibits MHC I and II expression 
gpUS2 US2 HCMV MHC I and II degradation 
gpUS11 US11 HCMV MHC I degradation 
gpUS6 US6 HCMV Inhibits TAP peptide transport 
gpUS8 US8 HCMV Binds MHC I molecules 
gpUS10 US10 HCMV Binds MHC I molecules 
gp48 m6 MCMV Targets MHC I to lysosomes 
gp40 m152 MCMV MHC I retention in the ERGIC 
















complement proteins directly to the surface of pathogens. Antibody-mediated 
complement lysis is an important mechanism for elimination of virus-infected 
cells. Therefore, a number of viruses encode complement regulatory proteins. 
Herpes simplex virus 1 (HSV-1) and Epstein Barr virus (EBV) both have 
homologs of regulators of complement activation (RCA) proteins, such as CD46 
and CD55 (Tortorella et al., 2000). Complement control proteins including CD46, 
CD55, and CD59 inhibit complement activation by regulating various stages 
within the complement cascade (Hirsch, 1982). While no cytomegalovirus 
encoded RCA homologs have been identified, cytomegaloviruses (CMVs) have 
evolved mechanisms for limiting complement activity. HCMV incorporates cellular 
CD55 and CD59 into the virion. Blocking CD55-mediated complement 
inactivation with antibodies decreases HCMV replication in fibroblast cell lines 
following stimulation with complement proteins (Spear et al., 1995). HCMV also 
upregulates expression of CD46 and CD55 on the surface of infected cells which 
decreases the accumulation of C3 convertases and protects the cells from 
complement mediated lysis (Spiller et al., 1996). Although the mechanisms differ 
from other herpesviruses, HCMV is able to induce complement inactivation. 
MCMV also induces CD46 expression on infected fibroblasts. This 
upregulation was mapped to a CMV responsive element within the CD46 
promoter (Nomura et al., 2002). Although mice typically express the complement 
regulator CRRY instead of CD46 (Holers, Kinoshita, and Molina, 1992), CD46 
expression was sufficient to decrease complement-mediated lysis of MCMV 
infected cells (Nomura et al., 2002). Viral manipulation of complement regulatory 
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proteins may explain the resistance of CMV infected fibroblasts to complement 
lysis when treated with virus specific antibodies which would be expected to 
induce the classical complement pathway (Spiller et al., 1997). Although virally 
infected cells are resistant to complement-mediated lysis, the specific viral 
proteins that interfere with complement activity during CMV infection have not 
been identified. 
II. Fc Receptor Homologs 
Clinical evidence supports a role for antibodies in limiting cytomegalovirus 
infection. The ability to modulate antibody-mediated immunity would therefore 
benefit cytomegalovirus pathogenesis. CMV infected cells can bind 
immunoglobulins in serum of seronegative individuals (Keller et al., 1976; 
Rahman et al., 1976; Westmoreland, St Jeor, and Rapp, 1976). This 
phenomenom was linked to the expression of Fc binding proteins (FcBP) on the 
surface of infected cells and are specific for IgG but not other Ig isotypes 
(Furukawa et al., 1975; Xu et al., 1989). Two HCMV FcBP have been identified, 
gp34 and gp68, which are encoded by the genes TRL11/IRL11 and UL119-
UL118, respectively (Atalay et al., 2002; Lilley, Ploegh, and Tirabassi, 2001). 
Both proteins have homology to cellular Fc receptors (FcR). Normally the FcRs 
from the host interact with the Fc region of Igs and mediate a number of effector 
functions including phagocytosis, release of inflammatory cytokines, and natural 
killer (NK) cell antibody mediated cellular cytotoxicity (ADCC) (Ravetch and 
Bolland, 2001). It has been spectulated that anti-viral antibody’s Fc region binds 
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the viral FcR instead of host FcRs, blocking antiviral activities.  Although the 
viral FcR from HSV-1 (gE-gI) protects infected cells in vitro from ADCC and 
complement activation (Dowler and Veltri, 1984; Dubin et al., 1994) and HSV-1 
mutants lacking gE-gI had lower titers in mice (Peng et al., 1998), the function of 
the HCMV-encoded FcR has not been determined. Recently it was shown that 
the HCMV FcRs interact with IgG differently than HSV-1 gE-gI and host FcRs 
suggesting the HCMV encoded proteins may have unique functions (Sprague et 
al., 2008). 
MCMV encodes an unrelated FcR, fcr-1 or m138. Although, m138 has no 
homology to the HCMV FcRs it has some conserved structural features with 
cellular FcRs and gE-gI (Thale et al., 1994). m138 is important for MCMV 
replication in vivo. Both wild-type and B cell deficient mice infected with a m138 
mutant MCMV had lower viral titers in several organs compared to wild-type 
MCMV, thus impaired growth of MCMV is not due to an enhanced humoral 
immune response in the absence of m138 (Crnkovic-Mertens et al., 1998; Jonjic 
et al., 1994). Interestingly, m138 downregulates expression of H60 and MULT-1, 
two ligands of the activating NK receptor, NKG2D. The importance of this 
downregulation in vivo was demonstrated by the ability of m138 MCMV to grow 
like wt MCMV in mice depleted of NK cells. The downregulation of MULT-1, but 
not H60, is due to defective cellular trafficking that results in degradation of the 
protein (Lenac et al., 2006). m138 also decreases cell surface trafficking of the 
costimulatory molecule B7-1 on dendritic cells (DCs), interfering with the ability of 
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these cells to activate antigen specific T cells (Mintern et al., 2006). Thus the 
MCMV FcR broadly affects both the innate and adaptive arms of the immune 
response, although probably not in the same manner as HSV-1 gI-gE. 
III. Interferon-Mediated Immunity 
Although interferons (IFNs) are induced early during CMV infection (Boyle, 
Pietropaolo, and Compton, 1999; Zhu, Cong, and Shenk, 1997), these viruses 
encode a number of proteins that interfere with and mitigate the effects of their 
activation (Aitken et al., 1999). The type I interferons IFN and IFN are part of 
the innate immune response to viral infections. The binding of IFN and IFN to 
the IFN receptor induces Jak/Stat signaling leading to the rapid upregulation of 
interferon-stimulated genes (ISGs), such as MHC class I molecules and various 
cytokines (Muller et al., 1994). Two HCMV immediate early gene products, 
72kDa immediate early 1 (IE1) protein (IE1-p72) and IE2 protein (IE86), interfere 
with IFN signaling. IE1-p72 inhibits the ISG transcriptional activator, ISGF3, from 
binding to the ISG promoter (Paulus, Krauss, and Nevels, 2006). IE86 blocks 
binding of the transcription factor NFB to the IFN promoter and leads to the 
downregulation of IFN expression in HCMV infected fibroblasts (Taylor and 
Bresnahan, 2005; Taylor and Bresnahan, 2006).  
The HCMV tegument protein pp65 (UL83) also blocks interferon activity, 
acting early during infection prior to transcription of the immediate early gene 
products (Browne et al., 2001). Microarray analysis has revealed pp65 
downregulates numerous ISGs although the mechanism for this is unclear 
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(Abate, Watanabe, and Mocarski, 2004). Conflicting reports have attributed this 
decrease to interference with either NFB activity or another transcriptional 
regulator, IRF-3, although both authors suggest pp65-mediated defects in 
nuclear localization of the transcription factors likely contribute to the decreased 
activity (Abate, Watanabe, and Mocarski, 2004; Browne and Shenk, 2003). The 
conservation of UL83 within CMV genomes and the in vivo attenuation of an 
MCMV lacking expression of the murine pp65 homolog (Morello, Cranmer, and 
Spector, 1999) illustrates the importance of pp65 for CMV survival. A virion 
constituent of rhesus CMV (rhCMV) also blocks interferon activation but this was 
not due to a UL83 homolog (DeFilippis and Fruh, 2005).  
The MCMV encoded protein, M27, interferes with both type I and type II 
(IFN) interferon activity by downregulating the signaling molecule, STAT2 
(Abenes et al., 2001; Zimmermann et al., 2005). M27 decreases transcription of 
constituents of the immunoproteasome. This IFN inducible proteasome 
enhances MHC class I processing of peptides for presentation (Khan et al., 
2004b). Therefore, M27 may not only protect MCMV from the direct antiviral 
effects of interferon induction but also interfere with presentation of viral peptides 
to CD8+ T cells, a common theme to be discussed below. 
MCMV and HCMV also encode proteins that interact with interferon 
induced gene products (Roy and Mocarski, 2007). The MCMV gene products 
m142 and m143 decrease activation of protein kinase R (PKR) (Valchanova et 
al., 2006), an enzyme that blocks protein synthesis in infected cells leading to 
impairment of viral replication. PKR is activated via dsRNA, which is produced 
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during transcription of complementary strands of the CMV genome. Both m142 
and m143 have dsRNA binding domains and may interfere with the binding of 
PKR with dsRNA, preventing its activation (Child et al., 2006). The HCMV 
encoded proteins TRS1 and IRS1 also have dsRNA binding capabilities (Hakki 
and Geballe, 2005; Hakki et al., 2006). Both proteins inhibit PKR function in 
vaccinia virus (VV) infected cells but their role in HMCV infection has not been 
evaluated (Child et al., 2004). 
IV. Natural Killer Cells 
Natural killer (NK) cells are cytotoxic cells of the innate immune response 
that play an important role in eliminating virus-infected cells early during infection. 
Signaling induced via both activating and inhibitory receptors regulates the 
cytotoxic activity of NK cells. Inhibitory receptors recognize certain MHC I alleles 
whereas a number of ligands can bind activating receptors to trigger NK cell 
mediated killing. NK cells are important for controling cytomegalovirus infections 
both in mice and humans (Bukowski et al., 1985; Gazitt, 2004). Therefore, it is 
not surprising the cytomegaloviruses encode numerous proteins that interfere 
with NK cell activity. 
HCMV encodes several proteins that interact with and alter NK cell 
responses. One of the earliest identified proteins, gpUL18, is encoded by the 
gene UL18 and is a MHC class I homolog (Beck and Barrell, 1988). gpUL18 
binds the 2-microglobulin (2m) and unlike the MHC homolog of MCMV, m144, 
gpUL18 also binds endogenous peptide (Browne et al., 1990; Fahnestock et al., 
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1995). gpUL18 binds the NK cell inhibitory receptor LIR-1 with higher affinity than 
host MHC I molecules (Cosman et al., 1997; Occhino et al., 2008; Yang and 
Bjorkman, 2008). However, the function of gpUL18 has not been clearly defined. 
gpUL18 expression both inhibits and activates NK cells in vitro and activates LIR-
1- cells further implicating complex mechanisms for NK cell modulation (Kim et 
al., 2004; Leong et al., 1998; Prod'homme et al., 2007; Reyburn et al., 1997; 
Wagner et al., 2007). Furthermore, clinical isolates of HCMV express pUL18 
variants with different LIR-1 binding affinities (Cerboni et al., 2006; Garrigue et 
al., 2007) that may have differential functions in vivo. In addition to its effect on 
NK cells, gpUL18 was recently shown to inhibit dendritic cell maturation and 
migration. While dendritic cells express LIR-1, whether this receptor mediates the 
effect of gpUL18 on dendritic cell activity was not determined (Wagner et al., 
2008). Collectively, current data suggests gpUL18 may impact the function of 
several cell types in vivo that may partially relate to its ability to bind and activate 
LIR-1. 
Recently, it was found the UL142 gene encodes a second HCMV MHC I 
homolog (Davison et al., 2003). Cells expressing gpUL142 are protected from NK 
cell lysis. However, this effect was not evaluated in the context of HCMV infection 
(Wills et al., 2005).  While the mechanism of this effect has yet to be determined, 
gpUL142 was recently shown to downregulate MICA, a ligand for the activating 
NK cell receptor, NKG2D (Chalupny et al., 2006). 
Some HCMV encoded proteins alter expression of NK cell receptor 
ligands. The protein product of UL141, gp141, decreases the expression of 
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CD155, a ligand for NK cell activating receptors. A common theme in CMV 
immune modulation, gp141 inhibits CD155 transport to the cell surface (Tomasec 
et al., 2005). This downregulation inhibits NK cell activity in vitro but further 
information regarding its function and impact in vivo remain to be answered. 
The UL16 encoded glycoprotein, gpUL16, binds a number of ligands of 
the NK cell activating receptor, NKG2D. gpUL16 binds members of the UL16-
binding protein (ULBP) and MIC family of proteins, which are NK ligands that are 
activated under conditions of cell stress (Sutherland, Chalupny, and Cosman, 
2001). In particular gpUL16 binds to ULBPs 1 and 2 (Cosman et al., 2001; Kubin 
et al., 2001) and MICB (Wu et al., 2003). gpUL16 downregulates these proteins, 
retaining them intracellularly in the ER or golgi network (Dunn et al., 2003; Rolle 
et al., 2003; Vales-Gomez et al., 2006). The interaction of gpUL16 with these 
ligands blocks NK cell activation in vitro (Kubin et al., 2001; Odeberg et al., 2003; 
Sutherland, Chalupny, and Cosman, 2001; Welte et al., 2003) and may represent 
a way for HCMV to inhibit the activation of NK cells due to replication induced cell 
stress. 
Interestingly, HCMV increases expression of the non-classical MHC I 
molecule, HLA-E, while downregulating expression of many other MHC I alleles 
(Wang et al., 2002). This upregulation is due to the expression of UL40, a HCMV 
encoded protein that contains a peptide sequence identical to the leader peptide 
bound by HLA-E (Cerboni et al., 2001; Tomasec et al., 2000; Ulbrecht et al., 
2000). Therefore, UL40 increases expression of HLA-E independent of TAP 
mediated peptide processing, which is inhibited during infection by the HCMV 
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encoded protein, gpUS6 (Lehner et al., 1997). HLA-E is a ligand for the inhibitory 
receptor CD94/NKG2A and the UL40 induced upregulation of HLA-E protects 
HCMV infected cells from NK cell lysis (Wang et al., 2002). 
 MCMV encodes two homologs of MHC class I molecules, although 
neither has similarity to the HCMV homolog, UL18 (Cavanaugh et al., 1996; 
Rawlinson, Farrell, and Barrell, 1996). The MCMV gene m157 has low sequence 
homology to MHC class I molecules but structural analysis shows it has features 
similar to MHC like folds (Arase et al., 2002). m157 is expressed on infected cells 
tethered by a gycosylphosphatidylinositol (GPI) anchor (Davis et al., 2008). m157 
binds the NK receptor, Ly49H, a member of the Ly49 family of inhibitory 
receptors (Arase et al., 2002; Kielczewska et al., 2007). Interestingly, the m157-
Ly49H interaction activates NK cells in vitro inducing NK cell cytotoxicity and 
cytokine and chemokine expression (Dorner et al., 2004; Smith et al., 2002). 
m157 activation of Ly49H is sufficient to override NK cell inhibition in cells 
expressing MHC I (Adams et al., 2007). Mice infected with a MCMV mutant 
lacking m157 are more susceptible to MCMV infection and have decreased NK 
cell activity (Bubic et al., 2004). Furthermore, MCMV replicates to higher titers in 
mouse strains that lack expression of Ly49GH receptors (Daniels et al., 2001), 
demonstrating the importance of this interaction to immune protection against 
MCMV. Although Ly49H protects against MCMV in laboratory mice, wild isolates 
of MCMV have m157 variants that fail to activate NK cells (Voigt et al., 2003). 
Mutations in m157 were also shown to accumulate following passage of MCMV 
in mice indicating a strong selective pressure in favor of m157 variants that inhibit 
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NK cell activation. This is further supported by the finding that m157 also binds 
the inhibitory NK receptor, Ly49I (Arase et al., 2002). Furthermore, m157 was 
recently shown to induce the functional impairment of some NK cell populations 
(Sun and Lanier, 2008; Tripathy et al., 2008). Therefore, activation of NK cells by 
m157 likely occurs less frequently in natural infection of mice. 
m144 is another MCMV encoded MHC I homolog (Hanson et al., 1999; 
Rawlinson, Farrell, and Barrell, 1996). m144 is expressed on the cell surface 
despite its inability to bind endogenous peptides (Chapman and Bjorkman, 
1998). m144 can inhibit NK cell cytolysis in vitro (Cretney et al., 1999), 
suggesting it serves as a decoy receptor to inhibit NK cell activation. Consistent 
with this idea, MCMV mutants without m144 expression grow poorly in mice due 
to enhanced NK cell activation (Farrell et al., 1997). While a flexible region within 
m144 that could potentially interact with host receptors has been identified 
(Natarajan et al., 2006), m144 has not been shown to bind any cellular receptor 
and its exact function remains unknown (Cretney et al., 1999). 
MCMV also encodes three proteins that downregulate ligands of the NK 
cell activating receptor, NKG2D. The protein encoded by m145 decreases 
expression of MULT-1 (Krmpotic et al., 2005), the m155 encoded glycoprotein 
downregulates H60 (Lodoen et al., 2004), and the m152 encoded glycoprotein 
(gp40) downregulates proteins of the RAE-1 family (Krmpotic et al., 2002; 
Lodoen et al., 2003). MCMV mutants lacking any one of these genes are 
attenuated in vivo and NK cell depletion restores MCMV growth. These results 
support a role for these proteins in inhibiting NK cell mediated clearance (Abenes 
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et al., 2004; Hasan et al., 2005; Krmpotic et al., 2002; Krmpotic et al., 2005). 
Although the exact mechanism of action is not known for these proteins, both 
m155 and gp40 act at a post-transcriptional step and likely interfere with 
trafficking of proteins to the cell membrane (Hasan et al., 2005; Krmpotic et al., 
2002; Lodoen et al., 2004). 
V. Cytokine Homologs 
Interleukin-10 (IL-10) is an immunosuppressive cytokine that 
downregulates inflammatory cytokine synthesis and interferes with antigen 
presentation by decreasing expression of MHC class II on antigen presenting 
cells (Moore et al., 2001). Members of the poxvirus and herpesvirus families, 
including some cytomegaloviruses, encode IL-10 homologs (Redpath, Ghazal, 
and Gascoigne, 2001). In contrast to other viral IL-10 homologs that have high 
similarity (80%) to their host IL-10, the HCMV IL-10 protein (cmvIL-10) has only 
limited homology to human IL-10 (hIL-10) (Kotenko et al., 2000). cmvIL-10 binds 
the IL-10 receptor (hIL-10R) albeit with lower affinity than hIL-10 (Kotenko et al., 
2000; Spencer et al., 2002). Nevertheless, it retains the capacity to induce a 
strong anti-inflammatory response. cmvIL-10 downregulates expression of IFN 
and TNF in peripheral blood mononuclear cells (PBMCs) and decreases 
expression of both MHC I and II on PBMCs and DCs (Chang et al., 2004; Raftery 
et al., 2004; Spencer et al., 2002). DCs exposed to cmvIL-10 inefficiently 
stimulated T cell proliferation (Chang et al., 2004) supporting its role in immune 
suppression. cmvIL-10 activates the phosphotidylinositol 3-kinase pathway 
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leading to inhibition of cytokine production (Spencer, 2007). Interestingly, cmvIL-
10 shows none of the stimulatory functions of hIL-10 such as promoting B cell 
differentiation or CD8+ T cell proliferation and thus may have retained only the 
immunosuppressive functions beneficial to viral replication in the host (Redpath, 
Ghazal, and Gascoigne, 2001). cmvIL-10 also alters function of non-leukocyte 
populations and was shown to interfere with placental cytotrophoblast behavior. 
Exposure of cytotrophoblasts to cmvIL-10 interfered with cytotrophoblast invasion 
,which could affect placental development leading to the sequelae observed 
following congenital CMV infections (Yamamoto-Tabata et al., 2004).  
An alternatively spliced version of cmvIL-10 was originally identified during 
latent HCMV infection and termed latency associated cmvIL-10 (LacmvIL-10) 
(Jenkins, Abendroth, and Slobedman, 2004). However, this transcript is also 
expressed during productive infection (Jenkins et al., 2008a). LacmvIL-10 fails to 
induce signaling pathways associated with IL-10R which implies LacmvIL-10 may 
not bind to IL-10R or, at least, differentially activates this receptor. LacmvIL-10 
also decreases MHC II expression on granulocyte-macrophage progenitors (GM-
Ps) and monocytes, both sites of CMV latency, possibly limiting clearance of 
latently infected cells (Jenkins et al., 2008b). 
A number of primate CMVs encode proteins similar to IL-10 (Lockridge et 
al., 2000) but only the function of the rhesus CMV (RhCMV) homolog has been 
evaluated to date. RhcmvIL-10 downregulates cytokine expression in PBMCs 
and MHC II molecule expression in monocytes (Spencer et al., 2002). Therefore, 
the function of human cmvIL-10 is conserved in RhCMV infection. Interestingly, 
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chimpanzee cytomegalovirus (CCMV) and MCMV do not encode IL-10 homologs 
(Lockridge et al., 2000). MCMV infection induces cellular IL-10 expression 
providing a mechanism for immune interference in the absence of a virally 
encoded IL-10 protein (Redpath et al., 1999). Therefore, IL-10 immune 
suppression, whether cellular or viral in origin, likely creates an environment that 
supports efficient viral replication in the host. 
VI. Cytokine Receptor Homologs 
The HCMV gene, UL144, encodes a protein with limited homology to the 
herpes simplex virus entry mediator (HVEM), a member of the tumor necrosis 
factor receptor (TNFR) superfamily (Benedict et al., 1999). UL144 is the only 
TNFR homolog identified to date in herpesviruses. The UL144 protein does not 
bind any known TNF ligand (Benedict et al., 1999; Lurain et al., 1999; Poole et 
al., 2006). UL144 has only been shown to bind a member of the Ig superfamily, B 
and T lymphocyte attenuator (BTLA) (Cheung et al., 2005), also a ligand of 
HVEM (Sedy et al., 2005). Binding of UL144 to BTLA blocks T cell proliferation 
and could impair lymphocyte responses to HCMV (Cheung et al., 2005). UL144 
activates TNFR-activated factor (TRAF6) leading to NFB activation and 
upregulation of the chemokine CCL22 (Poole et al., 2006). CCL22 is a 
chemoattractant of Th2 and regulatory T cells. Activation and attraction of these 
cells may help HMCV evade T cell-mediated antiviral activity. UL144 is located in 
the UL/b’ region of HCMV, a portion of the genome thought to encode potential 
virulence factors. Different UL144 genotypes have been identified in clinical 
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isolates however, all but one report have found no association between the 
different genotypes and CMV disease (Arav-Boger et al., 2006a; Arav-Boger et 
al., 2002; Bale et al., 2001; Heo et al., 2008; Lurain et al., 1999; Mao et al., 2007; 
Picone et al., 2005; Yan et al., 2008). Although there is much speculation on the 
role that UL144 plays in immune modulation, its role in CMV pathogenesis and 
survival in vivo is still unclear. 
VII. Viral Chemokine Homologs 
HCMV encodes two ORFS with homology to CXC chemokines, UL146 
and UL147 (Cha et al., 1996).  While no functional data is available for UL147, 
analysis of the protein product of UL146, vCXCL-1, demonstrated its capacity as 
a functional chemokine. vCXCL-1 was shown to bind exclusively to hCXCR2 with 
an affinity similar to that of the host chemokine, CXCL8. Additionally, vCXCL-1 
was able to induce chemotaxis and intracellular calcium release in human 
neutrophils, again to levels comparable to host chemokines (Penfold et al., 
1999). 
Chimpanzee CMV encodes homologs of UL146 and UL147 as well as the 
related gene UL146a. However, only the product of UL146 has been evaluated 
thus far. VCXCL-1CCMV induced chemotaxis and calcium release in human 
neutrophils. Additionally, it was shown to increase expression of adhesion 
molecules on the surface of neutrophils and reduce apoptosis in these cells 
(Miller-Kittrell et al., 2007). Taken together, the function of the HCMV and CCMV 
vCXCL-1s in vitro suggest the potential for these viral chemokines to alter the 
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response of neutrophils in the course of CMV infection. A mutant HCMV virus 
with a deletion of UL146-UL147 was unable to infect neutrophils but retained its 
ability to infect other cells providing additional evidence these proteins facilitate 
an interaction of CMV with neutrophils (Hahn et al., 2004). 
Due to the strict species specificity of CMV, in vivo characterization of 
UL146 and UL147 has been limited to sequence analysis of clinical HCMV 
isolates. UL146 is highly variable, differing as much as 60% among isolates (Heo 
et al., 2008). It was postulated that this variability might correlate with the severity 
of CMV disease however no clear relationship has been identified (Arav-Boger, 
Zong, and Foster, 2005; Bale et al., 2001; Bradley et al., 2008; Hassan-Walker et 
al., 2004). It was recently suggested the variability of UL146 may have arisen in 
early human populations and does not likely contribute to the pathogenesis of 
congenital infection (Bradley et al., 2008). 
HCMV also encodes genes with limited homology to CC chemokines. 
UL128 and UL130 both have signal sequences and conserved cysteine motifs 
similar to CC chemokines (Akter et al., 2003). It has yet to be determined 
whether these proteins function as chemokines. Interestingly, the UL128-131 
locus was found to be necessary for endothelial cell and leukocyte tropism based 
on the inability of HCMV UL128-131 deletion mutants to infect these cell types 
(Hahn et al., 2004). This likely explains the loss of endothelial cell tropism in lab-
adapted strains of HCMV, a number of which were shown to have deletions or 
mutations in at least one gene from this region (Akter et al., 2003). The UL128-
131 proteins have recently been shown to interact with gH/gL complexes that 
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mediate entry of CMV into endothelial and epithelial cells, in contrast to the 
gH/gL/gO complexes that mediate virus entry into fibroblasts (Wang and Shenk, 
2005a; Wang and Shenk, 2005b).  
The best characterized of the CMV chemokines is the CC chemokine 
homolog of MCMV. Originally identified as the m131 gene product, MCK1, 
transcript analysis during MCMV infection determined that a spliced product of 
m131 and m129, referred to as MCK2 was the only transcript identified from this 
locus. The CC chemokine domain is confined to the MCK1 coding region and is 
followed by a long carboxy-terminal domain (199 amino acids) with no known 
homology, making MCK2 considerably longer than other chemokines 
(MacDonald et al., 1999; MacDonald, Li, and Virgin, 1997). In contrast to UL146, 
the DNA sequence of MCK2 is highly conserved in isolates from wild mice 
(Smith, Shellam, and Redwood, 2006).   
Initial studies in vitro showed MCK1 induced higher levels of Ca2+ 
mobilization in peritoneal exudates cells from MCMV infected mice than cells 
from uninfected mice. This demonstrates that MCK1 could activate cells recruited 
to the site of MCMV infection (Saederup et al., 1999). MCK2 is important for viral 
spread within the host. When a recombinant MCMV with mutations in the m131 
gene generated via point mutations or insertions was inoculated into mice, these 
recombinants showed a defect in dissemination to the salivary gland. Mice 
infected with these mutants developed less inflammation at the site of 
inoculation, reduced secondary viremia, as well as lower viral titers in the salivary 
glands, a site of dissemination following secondary viremia (Fleming et al., 1999; 
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Saederup et al., 2001). This was the first direct evidence that a CMV encoded 
chemokine is important for the dissemination of the virus in its host. Additional 
work identified the MCK2-recruited cell type as a late myeloid progenitor, 
consistent with reports that CMV infects and can remain latent in cells of the 
myelomonocytic lineage (Noda et al., 2006). 
Rat CMV (RCMV) encodes a CC chemokine with similarity to both m131 
and m129, having N-terminal chemokine homology and a long carboxy-terminus 
like that of MCK2 (Vink, Beuken, and Bruggeman, 2000). Rats infected with 
RCMV deletion mutants lacking pr131 expression had reduced viral loads in the 
spleen and salivary glands. Additionally these mice had reduced swelling and 
macrophage infiltration at the site of virus inoculation (Kaptein et al., 2004). 
Therefore, the r131-encoded protein, pr131, appears to be a functional homolog 
of MCK2. 
Guinea pig CMV (GPCMV) has one gene with homology to CC 
chemokines, though it lacks positional or sequence similarity to the m131/m129 
genes of MCMV. GPCMV-MIP is most similar to the cellular chemokines, 
CCL3/CCL4 (MIP-1/) and CCL14 (HCC-1). GPCMV-MIP induced Ca2+ flux 
and migration of cells expressing HCCR-1 but did not elicit a response from cells 
expressing other CC receptors. CCL14 is known to increase the proliferation of 
monocyte progenitors, therefore GPCMV-MIP may enhance the proliferation 
and/or recruitment of permissive cells consistent with the role of MCK2 (Haggerty 
and Schleiss, 2002). 
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VIII. Chemokine Receptor Homologs 
In addition to viral chemokine homologs, CMVs encode proteins with 
homology to chemokine receptors (Chee et al., 1990). Chemokine receptors are 
members of the G-protein coupled receptor (GPCR) family (Murphy, 1994). The 
four chemokine receptor homologs encoded by the cytomegaloviruses have 
homology to the CC chemokine receptor family. Two genes, UL33 and UL78, are 
conserved among all sequenced CMVs, while primate CMVs encode two 
additional GPCRs, US27 and US28 (van Cleef et al., 2006). 
The US28 encoded protein (pUS28) is the best characterized of the 
GPCR homologs. US28 has the highest sequence homology to the cellular 
receptor, CCR1, and binds a number of CC chemokines including CCL5 
(RANTES), CCL2 (MCP-1), CCL3 (MIP-1), and CCL4 (MIP-1) (Gao and 
Murphy, 1994; Kuhn, Beall, and Kolattukudy, 1995). Interestingly, pUS28 binds 
with highest affinity to the CX3C chemokine, CX3CL1 (fractalkine) (Kledal, 
Rosenkilde, and Schwartz, 1998). Upon binding, pUS28 induces chemokine 
internalization, removing chemokines from the extracellular environment 
(Bodaghi et al., 1998; Michelson et al., 1997; Vieira et al., 1998). Consistently, 
pUS28 inhibits monocyte migration in vitro and media from infected monolayers 
lack CCL5 and CCL2, which are present in media of untreated cells (Randolph-
Habecker et al., 2002). Constitutive endocytosis and recycling of pUS28 
contributes to chemokine internalization however chemokine binding is not 
sufficient to induce constitutive endocytosis of pUS28 (Fraile-Ramos et al., 
2001). By acting as a “chemokine sink”, pUS28 could alter or inhibit chemokine-
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dependent immune responses. The related chemokine homolog, pUS27, also 
shows some ability to internalize chemokines (Bodaghi et al., 1998; Margulies 
and Gibson, 2007), indicating the important function of these viral GPCRs.  
pUS28 elicits ligand-dependent signaling, triggering calcium mobilization 
upon binding to CCL5, CCL2, CCL3 and CCL7. pUS28 ulitilizes the G proteins  
Gi and G16 to mediate calcium mobilization upon binding of CCL5 or CCL7 
(Billstrom et al., 1998; Casarosa et al., 2001; Gao and Murphy, 1994). 
Interestingly, G16 expression is restricted to hematopoietic cells (Wilkie et al., 
1991). Since CMV has a tropism for many cells of this lineage, pUS28 may alter 
G16 signaling in these cells to benefit the CMV life cycle. pUS28 also induces 
agonist-dependent migration of smooth muscle cells (SMCs). Migration of SMCs 
in response to pUS28 requires the protein tyrosine kinase (PTK) pathway, 
indicating pUS28 activates a number of cellular pathways in vitro (Streblow et al., 
1999). As with many CMV proteins, the effects of pUS28 vary depending on the 
system and cell types analyzed. 
Like the Kaposi’s sarcoma-associated herpesvirus (KSHV) GPCR 
homolog ORF74 (McLean et al., 2004), pUS28 can constitutively activate several 
signaling pathways, including phospholipase C (PLC), NFB, NFAT, and cAMP-
responsive element (CRE)-dependent pathways (Casarosa et al., 2001; Fraile-
Ramos et al., 2001; McLean et al., 2004; Miller et al., 2003; Stropes and Miller, 
2008; Waldhoer et al., 2002). CC chemokines do not enhance signaling, 
although CX3CL1 acts as a partial inverse agonist, decreasing the levels of 
pUS28 constitutive activity (Casarosa et al., 2001; Waldhoer et al., 2002).  
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Interestingly, the constitutive endocytosis of pUS28 occurs independently of its 
constitutive signaling and different domains of pUS28 control these two 
phenomenon (Fraile-Ramos et al., 2001). However, the constitutive signaling of 
pUS28 contributes to the induction of caspase-dependent cell death in vitro 
(Pleskoff et al., 2005). Furthermore, pUS28 can induce transformation of NIH3T3 
cells and promote tumor formation in nude mice. Mice inoculated with cells 
expressing a mutated pUS28 that lacks constitutive activity show attenuated 
tumor formation demonstrating the importance of constitutive signaling in pUS28-
mediated tumor formation (Maussang et al., 2006). 
Despite extensive research on the function of pUS28, its role in CMV 
pathogenesis in vivo is still unknown. pUS28 may alter the immune response by 
sequestering host chemokines or activate signaling pathways that contribute to 
viral replication or spread. pUS28-induced SMC migration may play a role in the 
accelerated vascular disease associated with HCMV (Melnick, Adam, and 
Debakey, 1993; Zhou et al., 1996). Since HCMV has been identified in certain 
cancers (Cobbs et al., 2002; Harkins et al., 2002), pUS28 may contribute to 
tumor formation in these individuals.  
The UL33 gene is conserved in all  herpesviruses, including HCMV 
(UL33), RCMV (R33), and MCMV (M33). While no ligands have been identified 
for either pUL33 or pR33, pM33 is activated by CCL5 (Melnychuk et al., 2005). 
All three viral proteins show constitutive activity, although they differentially 
activate specific signaling pathways (Casarosa et al., 2003; Gruijthuijsen et al., 
2002; Sherrill and Miller, 2006; Waldhoer et al., 2002). While not essential for 
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viral replication in vitro, both pR33 and pM33 are important for replication of CMV 
in the salivary gland (Beisser et al., 1998; Davis-Poynter et al., 1997; Margulies, 
Browne, and Gibson, 1996). In MCMV, this defect was linked to the constitutive 
activity of pM33 (Case et al., 2008) and illustrates the importance of constitutive 
signaling in vivo. Like pUS28, pM33 and pR33 induce SMC migration (Melnychuk 
et al., 2005; Streblow et al., 2005). Taken together, this suggests GPCRs of the 
UL33 family alter cellular trafficking during CMV infection, which may contribute 
to viral pathogenesis. 
UL78 gene family encoded proteins have only limited homology to known 
chemokine receptors (van Cleef et al., 2006). Nevertheless, this gene is 
conserved in all  herpesviruses suggesting they have some role in the life cycle 
of herpesviruses. The UL78 proteins of MCMV and RCMV, pM78 and pR78, 
respectively, are important for viral replication in vitro and in vivo (Beisser et al., 
1999; Kaptein et al., 2003; Oliveira and Shenk, 2001). The HCMV homolog, 
pUL78, is not required for replication of HCMV in vitro (Michel et al., 2005) thus 
MCMV and RCMV may be more dependent on its function for viral replication. 
Although, members of the UL78 family are clearly important for viral replication 
for some CMVs, data regarding their specific function as GPCRs is not currently 
available. 
IX. Viral Chemokine Binding Proteins 
Chemokine binding proteins (CBPs) are virally encoded secreted proteins 
that competively bind chemokines and interfere with their interactions with 
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cellular receptors. Unlike viral chemokine and chemokine receptor homologs, 
which were likely acquired from the host, CBPs generally show no homology to 
known proteins and homology of these proteins across among viruses is not 
conserved (Seet and McFadden, 2002). Until recently, no CMV species was 
known to encode a CBP. However, a HCMV encoded protein, p21.5, has been 
identified with chemokine binding properties. mRNA transcripts of the gene 
UL21.5 are packaged in the HCMV virion and thus may function soon after viral 
entry into the cell. Although many CBPs interact with multiple chemokines (Lalani 
and McFadden, 1997), p21.5 is unusual in that it selectively binds CCL5 
(RANTES) in vitro blocking the interaction of the chemokine with its cellular 
receptors (Lalani and McFadden, 1997; Wang, Bresnahan, and Shenk, 2004). 
No data is available which evaluates the ability of p21.5 to interfere with CCL5 
function in vivo and its effect on viral survival. 
X. Apoptosis 
Apoptosis is a mechanism for programmed cell death that plays an 
important role in the elimination of cells during development and virally infected 
cells as part of the host’s innate immunity (O'Brien, 1998; Vaux and Korsmeyer, 
1999). Many viruses including CMVs have strategies to prevent apoptosis 
(Mocarski, 2002). HCMV encodes two proteins in particular that directly interfere 
with the apoptosis pathway. The HCMV UL36 gene encodes a viral inhibitor of 
caspase-8 induced apoptosis (vICA) and exon 1 of UL37 encodes the viral 
mitochondrial inhibitor of apoptosis (vMIA) (Goldmacher, 2005). 
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vICA protects cells in vitro from extrinsic apoptosis mediated through 
ligation of  the death receptors, Fas and TNFR-1 (Skaletskaya et al., 2001). vICA 
is a virion constituent (Patterson and Shenk, 1999) and inhibits apoptosis soon 
after HCMV enters the cell. vICA inhibits caspase-8 activation by interacting with 
the proenzyme, procaspase-8 (Skaletskaya et al., 2001). vICA prevents the 
interaction of procaspase-8  with the adapter protein, Fas-associated death 
domain (FADD), which inhibits the processing of procaspase-8 to its active form 
(Andoniou and Degli-Esposti, 2006). Therefore, vICA is functionally similar, 
although mechanistically distinct from, cellular and viral FLICE inhibitory proteins 
(FLIPS), which also interfere with caspase-8 activation (Thome et al., 1997). 
However, vICA has no homology with any identified FLIPs.  
vICA is dispensable for replication and some HCMV lab strains have 
inactivating mutations in the UL36 gene (Patterson and Shenk, 1999; 
Skaletskaya et al., 2001). Nevertheless, vICA homologs are conserved in the 
genomes of all sequenced -herpesviruses except for guinea pig CMV (GPCMV) 
where no positional homolog has been identified (Goldmacher, 2005). The vICA 
homologs of RhCMV and MCMV, Rh36 and M36, respectively, also have 
antiapoptotic activities in vitro (McCormick et al., 2003). Therefore, vICA may 
have a conserved function in the life cycle of these viruses. 
In contrast to vICA, vMIA protects cells from intrinsic apoptosis induced 
following damage to the mitochondrial membrane (Goldmacher, 2002; 
Goldmacher et al., 1999; McCormick et al., 2005). vMIA only blocks Fas-
mediated apoptosis in cells in which apoptosis proceeds through a mitochondrial-
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dependent step (Skaletskaya et al., 2001). vMIA has not been identified in virion 
particles and inhibits apoptosis at later times compared to vICA consistent with a 
requirement for transcription of vMIA following viral entry into the cell 
(Goldmacher, 2002). vMIA function requires localization at the mitochondria 
where it induces structural changes and inhibits mitochondrial release of 
cytochrome c, blocking downstream events in the apoptosis pathway 
(Goldmacher et al., 1999). vMIA was initially shown to interact with adenine 
nucleotide translocator (ANT), a protein involved in regulating permeability of the 
mitochondrial membrane (Arnoult et al., 2004; Goldmacher et al., 1999). 
However, binding of this protein does not correlate with vMIA function and is 
likely a nonspecific interaction (Arnoult et al., 2004). vMIA also binds the 
proapoptotic protein, Bax, inducing aggregation of Bax molecules at the 
mitochodrial membrane preventing membrane permeabilization (Poncet et al., 
2004). The screening of proteins that interact with the antiapoptotic domain of 
vMIA identified the protein growth arrest and DNA damage 45 (GADD45). 
GADD45 enhances vMIA-induced apoptosis possibly protecting it from 
proteasomal degradation (Smith and Mocarski, 2005). Sequence homologs of 
vMIA have only been found in primate CMVs (McCormick et al., 2003). However 
a recently identified gene product in MCMV, m38.5, was shown to interact with 
Bax and inhibit apoptosis (McCormick et al., 2005; Norris and Youle, 2008). 
Therefore, vMIA functional homologs may exist in other cytomegaloviruses. 
The MCMV protein encoded by M45 has no homology to known apoptosis 
inhibitors but was recently shown to supress the cell death pathway in a manner 
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unique to viral inhibitors of apoptosis (Brune et al., 2001). M45 interacts with the 
receptor-interacting protein kinase I (RIPI) via a RIP homotypic interaction motif 
(RHIM). By binding to RIP, M45 intereferes with signaling via cell death receptors 
protecting virus infected cells from apoptosis (Upton, Kaiser, and Mocarski, 
2008).  
 
Adaptive Immune Response 
XI. T Cell Mediated Immunity 
T cell mediated immune responses, particularly CD8+ T cell dependent 
responses, are integral to the clearance of cytomegalovirus infections (Edward S. 
Mocarski, 2007). Cytomegaloviruses impair T cell activation by interfering with 
both MHC class I and II antigen processing and presentation. Although this has 
been shown in vitro, Th or CTL responses are generated during CMV infection in 
vivo (Alcami and Koszinowski, 2000; Hengel et al., 1999; Khan et al., 2004a; 
Trzonkowski et al., 2003). 
The US region of the HCMV genome encodes a number of endoplasmic 
reticulum (ER) resident glycoproteins that alter MHC expression (Jones et al., 
1995). The first of these proteins to be expressed following HCMV infection is the 
US3 encoded immediate early protein, gpUS3, which likely interferes with T cell 
recognition early during viral replication (del Val et al., 1992; Thrower et al., 
1996). gpUS3 binds MHC I molecules and retains them in the ER, inhibiting 
antigen presentation to CD8+ T cells (Ahn et al., 1996; Jones et al., 1996; Jun et 
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al., 2000). The transmembrane domains of gpUS3 are responsible for binding 
MHC I (Lee et al., 2000; Zhao and Biegalke, 2003), however, luminal regions of 
gpUS3 are needed for retention of MHC in the ER (Lee, Park, and Ahn, 2003; 
Lee et al., 2000; Misaghi et al., 2004; Zhao and Biegalke, 2003). Interestingly, 
gpUS3 also binds tapasin and this interaction prevents tapasin-mediated protein 
loading of MHC I molecules. Therefore, gpUS3 only retains MHC I alleles that 
are tapasin dependent (Park et al., 2004). An alternatively spiced form of gpUS3 
competively binds tapasin and may represent a regulatory mechanism for gpUS3 
activity (Shin et al., 2006). gpUS3 also binds and downregulates MHC II which 
subsequently decreases antigen presentation to CD4+ T cells. However, this 
interaction is not as well characterized as that of gpUS3 with MHC I molecules 
(Hegde et al., 2002).  
In contrast to gpUS3, the binding of MHC I molecules to the US2 and 
US11 encoded HCMV proteins, gpUS2 and gpUS11, respectively, leads to the 
rapid degradation of MHC I molecules (Wiertz et al., 1996a; Wiertz et al., 1996b). 
Both proteins bind MHC I molecules resulting in their removal from the ER to the 
cytosol where they undergo proteasome-dependent degradation (Ahn et al., 
1996; Wiertz et al., 1996a; Wiertz et al., 1996b). This process requires a 
functional ubiquitination system although only gpUS2 specifically depends on 
MHC I ubiquitination for protein degradation (Hassink et al., 2006; Kikkert et al., 
2001; Shamu et al., 1999). In addition to the ubiquitin system, gpUS2 and 
gpUS11 associate with other cellular proteins that facilitate recognition and 
removal of proteins via the endoplasmic reticulum associated protein degradation 
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(ERAD) pathway (Shamu et al., 2001; Tirosh et al., 2005). gpUS2 forms a 
complex with the chaperones, calnexin, BiP, and calreticulin to mediate MHC I 
degradation (Oresic and Tortorella, 2008). In contrast, gpUS11-dependent 
protein degradation requires Derlin-1, a protein that plays a role in the removal of 
misfolded proteins (Lilley and Ploegh, 2004).  
Why HCMV encodes two different proteins that target MHC I for 
degradation is unclear. gpUS2 and gpUS11 differ in their specificities for MHC I 
alleles. While they may overlap in function, they likely mediate distinct effects on 
MHC I expression (Machold et al., 1997). This difference in specificity is likely the 
result of different binding requirements for gpUS2 and gpUS11. The luminal 
portion of gpUS2 interacts with residues in the 2/3 region of the luminal domain 
of MHC I molecules (Gewurz et al., 2001a; Gewurz et al., 2001b). Specifically, 
gpUS2-mediated degradation requires the presence of an arginine at residue 181 
of MHC I molecules. However, this residue is not sufficient for degradation of 
some MHC I alleles and other residues must be important for these molecules 
(Thilo et al., 2006). The luminal region of gpUS11 is also important for MHC I 
binding, however, gpUS11 interacts with residues in the 1/2 domain of MHC I 
molecules (Barel et al., 2003; Lee et al., 2005). Additionally, gpUS2, but not 
gpUS11, interferes with CD4+ T cell recognition by downregulating MHC II 
molecules in a number of different cell types in vitro (Hegde and Johnson, 2003; 
Hegde et al., 2002; Tomazin et al., 1999).  
The HCMV US6 gene, encodes another glycoprotein, gpUS6, that 
downregulates MHC I expression (Ahn et al., 1997; Hengel et al., 1997; Lehner 
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et al., 1997). Like the other US proteins that interfere with MHC I expression, 
gpUS6 mediates retention of MHC I via its luminal domain (Ahn and Hayward, 
1997). However, the gpUS6 mechanism is unique in that it binds to TAP-1 and 
TAP-2 heterodimers (Halenius et al., 2006) in the transporter associated with 
antigen processing (TAP) complex (Hengel et al., 1997; Kyritsis et al., 2001; 
Lehner et al., 1997). Through its association with TAP, gpUS6 prevents the 
binding of ATP to TAP (Hewitt, Gupta, and Lehner, 2001) and subsequent TAP 
peptide translocation (Ahn et al., 1997; Hengel et al., 1997). gpUS6 expression is 
solely responsible for the inhibition of TAP in HCMV infected cells (Hengel et al., 
1996) and downregulates all MHC I alleles tested (Llano et al., 2003). In addition 
to impairing CD8+ T cell responses, this decrease in MHC I expression also 
makes infected cells susceptible to NK cell cytotoxicity (Llano et al., 2003), which 
may explain why CMVs have evolved mechanisms for preventing NK lysis (see 
section IV).  
Two additional HCMV encoded proteins, gpUS8 and gpUS10, bind MHC I 
molecules. However, neither protein downregulates cell surface MHC I 
expression, although gpUS10 slows MHC I maturation and egress from the ER. 
The function of these proteins in HCMV infection is currently unknown (Furman 
et al., 2002; Tirabassi and Ploegh, 2002). 
Other cytomegaloviruses have homologs of some of the HCMV US family 
members. CCMV encodes a gpUS6 homolog that binds TAP. However, this 
interaction doesn’t downregulate MHC I expression in chimpanzee cells in vitro, 
making the function of this homolog unclear (Dugan and Hewitt, 2008). In 
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contrast, RhCMV encodes homologs of gpUS2, gpUS3, gpUS6, and gpUS11 
(Hansen et al., 2003). Each of the RhCMV proteins functions similarly to its 
HCMV counterpart (Pande et al., 2005). Therefore, RhCMV may be a valuable 
model system for analyzing the function of these proteins during CMV infection in 
vivo. 
MCMV encodes three proteins unrelated to those of HCMV that interfere 
with MHC I expression in infected cells. gp48, gp40, and gp34 are encoded by 
m6, m152, and m4, respectively. Both gp40 and gp48 inhibit antigen presentation 
to CD8+ T cells in vitro (Reusch et al., 1999; Ziegler et al., 1997). gp40 and gp48 
bind MHC I molecules and retain them intracellularly (Krmpotic et al., 1999; 
Reusch et al., 1999; Ziegler et al., 1997), although each protein does so via 
different mechanisms. gp40 retains MHC I molecules in the ER-Golgi 
intermediate compartment (ERGIC)-cis golgi network (Ziegler et al., 1997) 
whereas gp48 binds to MHC I molecules and targets them to lysosomes for 
degradation (Reusch et al., 1999). Deletion of m152 restores MHC expression in 
MCMV infected cells suggesting gp40 is the main regulator of MHC I 
downregulation (Holtappels et al., 2006; Kavanagh et al., 2001). However, gp48 
cooperates with gp40 to enhance MHC I retention in vitro (Wagner et al., 2002). 
gp48 and gp40 also show different specificities for MHC I alleles and thus are 
both required for efficient class I downregulation in certain cell types (Hengel et 
al., 2000; LoPiccolo et al., 2003). Surprisingly, the presence of m152 does not 
impact the CTL response in mice based on studies using recombinant MCMVs. 
Therefore, the in vivo role of m152 as well as m4 and m6 is not clear (Gold et al., 
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2002; Munks et al., 2007; Pinto et al., 2006). One possible explanation for this 
lack of CTL alteration in vivo is cross-priming of CD8+ T cells by uninfected 
antigen presenting cells (APCs), which could circumvent function of gp40 in mice 
(Munks et al., 2007). 
The MCMV protein gp34 also associates with MHC I molecules (Kleijnen 
et al., 1997; Lu, Kavanagh, and Hill, 2006). In contrast to gp40 and gp48, gp34 
can decrease the intracellular retention of MHC I molecules (Kleijnen et al., 1997; 
Wagner et al., 2002). However, this phenomenon is seen only in the absence of 
m6 (gp48) suggesting gp48 expression may antagonize the function of gp34 and 
provide a mechanism to regulate the extent of MHC I expression in infected cells 
(Holtappels et al., 2006; Wagner et al., 2002). 
 
Conclusion 
It is clear based on the numerous viral proteins that respond to the host’s 
denfese mechanisms that the relationship of the cytomegaloviruses with their 
hosts is complex. CMVs can influence the magnitude and quality of both innate 
and adaptive immune responses. Despite this the host still launches a robust 
immune response to CMV but not before the virus establishes latency within the 
host. Therefore CMV infection does not eliminate host immunity but modulates it 
to allow survival of both the virus and the host, as both are important to the life 
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